

1 **Exocrine gland-resident memory CD8<sup>+</sup> T cells use mechanosensing for tissue surveillance**

2

3 Nora Ruef<sup>1,\*</sup>, Jose Martínez Magdaleno<sup>1,\*</sup>, Xenia Ficht<sup>2</sup>, Vladimir Purvanov<sup>3</sup>, Matthieu Palayret<sup>1</sup>,  
4 Stefanie Wissmann<sup>1</sup>, Petra Pfenninger<sup>1</sup>, Bettina Stolp<sup>4</sup>, Flavian Thelen<sup>5</sup>, Juliana Barreto de  
5 Albuquerque<sup>6</sup>, Philipp Germann<sup>7</sup>, James Sharpe<sup>7,8,9</sup>, Jun Abe<sup>1</sup>, Daniel F. Legler<sup>3,10,11</sup>, Jens V.  
6 Stein<sup>1,\*\*</sup>

7

8 <sup>1</sup> Department of Oncology, Microbiology and Immunology, University of Fribourg, 1700 Fribourg,  
9 Switzerland

10 <sup>2</sup> Department of Biosystems Science and Engineering, ETH Zürich Mattenstrasse 22, 4058, Basel,  
11 Switzerland

12 <sup>3</sup> Biotechnology Institute Thurgau (BITg) at the University of Konstanz, 8280 Kreuzlingen,  
13 Switzerland

14 <sup>4</sup> Department for Infectious Diseases, Integrative Virology, Center for Integrative Infectious Disease  
15 Research, University Hospital Heidelberg, 69120 Heidelberg, Germany

16 <sup>5</sup> Department of Medical Oncology and Hematology, University of Zürich and University Hospital  
17 Zürich, 8091 Zürich, Switzerland

18 <sup>6</sup> Division of Experimental Pathology, Institute of Pathology, University of Bern, 3008 Bern,  
19 Switzerland

20 <sup>7</sup> Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST),  
21 08003 Barcelona, Spain

22 <sup>8</sup> European Molecular Biology Laboratory (EMBL) Barcelona, 08003 Barcelona, Spain

23 <sup>9</sup> Institutio' Catalana de Recerca i Estudis Avancats (ICREA), 08010 Barcelona, Spain

24 <sup>10</sup> Faculty of Biology, University of Konstanz, 78464 Konstanz, Germany

25 <sup>11</sup> Theodor Kocher Institute, University of Bern, 3011 Bern, Switzerland

26

27 \* Equal contribution

28 \*\* To whom correspondence should be addressed

29 Contact: Jens V. Stein

30 Department of Oncology, Microbiology and Immunology  
31 University of Fribourg  
32 Ch. du Musée 5  
33 CH-1700 Fribourg  
34 email: [jens.stein@unifr.ch](mailto:jens.stein@unifr.ch)

35 **Abstract**

36 Tissue-resident CD8<sup>+</sup> T cells (T<sub>RM</sub>) constitutively scan peptide-MHC (pMHC) in their organ of  
37 residence to intercept microbial spread. Recent data showed that T<sub>RM</sub> lodged in exocrine glands  
38 perform tissue scanning in the absence of any chemoattractant or adhesion receptor signaling,  
39 thus bypassing the requirement for canonical migration-promoting factors. The signals eliciting this  
40 non-canonical motility mode and its relevance for organ surveillance have remained unknown.  
41 Using mouse models of viral infections, we report that exocrine gland T<sub>RM</sub> autonomously generated  
42 front-to-back F-actin flow for locomotion, accompanied by high cortical actomyosin contractility and  
43 leading edge bleb formation. The distinctive mode of exocrine gland T<sub>RM</sub> locomotion was triggered  
44 by sensing physical confinement, and closely correlated with nuclear deformation, which acts as a  
45 mechanosensor via an arachidonic acid and Ca<sup>2+</sup>-signaling pathway. In contrast, naïve CD8<sup>+</sup> T  
46 cells or T<sub>RM</sub> surveilling microbe-exposed epithelial barriers did not show mechanosensing capacity.  
47 Inhibition of nuclear mechanosensing disrupted exocrine gland T<sub>RM</sub> scanning and impaired their  
48 ability to intercept target cells. In sum, confinement suffices to elicit autonomous T cell surveillance  
49 in glands with restricted chemokine expression, and constitutes a complementary scanning  
50 strategy to chemosensing-dependent migration.

51

## 52    **Introduction**

53    CD8<sup>+</sup> T cell-mediated protection against viral infections hinges on the rapid detection of cognate  
54    pMHC presented on antigen-presenting and infected host cells. To expedite this process, CD8<sup>+</sup> T  
55    cells integrate biochemical cues of their microenvironment via chemoattractant and adhesion  
56    receptors (1). During the course of an immune response, CD8<sup>+</sup> T cells adapt their adhesion and  
57    chemoattractant receptor expression pattern to their differentiation status. These expression  
58    patterns enable clonal selection in lymphoid organs, followed by elimination of infected cells in  
59    inflamed tissue and tissue surveillance in the memory phase (2). More specifically, naïve and  
60    central memory CD8<sup>+</sup> T cells (T<sub>N</sub> and T<sub>CM</sub>, respectively) express CD62L and CCR7 for homing to  
61    secondary lymphoid organs (SLO), while effector and effector memory T cells (T<sub>EFF</sub> and T<sub>EM</sub>,  
62    respectively) display high surface levels of inflammatory chemokine and adhesion receptors to  
63    enter non-lymphoid tissues. Chemokine and adhesion receptors are also critical for interstitial  
64    scanning within target organs, the prerequisite for antigen-specific protection afforded by T<sub>EFF</sub> (3–  
65    5). Finally, tissue-resident memory T cells (T<sub>RM</sub>) express numerous chemokine and adhesion  
66    receptors including CXCR3, CXCR6, CD49a and CD103, which contribute to their long-term  
67    persistence in their tissue of residence and to the surveillance of epithelial barriers exposed to  
68    microbes (6–13).

69    Their vigorous scanning behavior makes CD8<sup>+</sup> T cells a valuable model to study amoeboid cell  
70    migration, a heterogeneous phenomenon encompassing forward and retrograde F-actin flow, as  
71    well as different types of protrusions such as lamellipodia, pseudopods and blebs (14–19). Recent  
72    studies have dissected the precise mode of amoeboid migration of T<sub>N</sub>. These cells generate a  
73    CCR7-driven retrograde cortical F-actin flow dependent on the guanine exchange factor (GEF)  
74    DOCK2 and its downstream targets Rac1 and Rac2 (20–23). Retrograde F-actin flow transmits  
75    weak forces via the integrin LFA-1 to its receptor ICAM-1 displayed on stromal cells, providing the  
76    traction force for rapid T<sub>N</sub> locomotion within the lymphoid parenchyma without inducing substantial  
77    adhesion (23–25).

78    In addition to the paradigmatic T cell migration driven by chemosensing of external cues, we have  
79    recently uncovered a distinct motility signature displayed by submandibular salivary gland (SMG)  
80    CD8<sup>+</sup> T<sub>RM</sub> (26). Although these cells exhibit high *in vivo* migration speeds of 6–7 μm/min, we did not



81 find evidence for a substantial contribution for chemoattractant and adhesion receptors during  
82 homeostatic organ surveillance, since neither pertussis toxin treatment (to block  $G_{\alpha i}$ -coupled  
83 receptors) nor integrin inhibition had an effect on their motility. Instead, SMG  $CD8^+ T_{RM}$   
84 spontaneously migrate with frequent shape changes in the absence of chemoattractants and  
85 specific adhesive interactions (26), perhaps as an adaptation to the chemokine-poor milieu of non-  
86 inflamed salivary glands (27). This is in contrast to epidermal  $CD8^+ T_{RM}$ , which require external  
87 chemoattractants for motility (8, 26). In line with our findings, T cell lines are able to migrate in  
88 complete absence of chemokine and adhesion receptors, using topography-dependent force  
89 transmission (28). Yet, the cues that trigger receptor-independent motility of  $CD8^+ T_{RM}$  lodging in  
90 resting glands, and the relevance of this non-canonical migration to intercept Ag-presenting cells  
91 remain unknown to date.

92 Here, we have systemically compared SMG  $T_{RM}$  motility to the canonical chemosensing-driven  $T_N$   
93 amoeboid migration. In the absence of external biochemical cues,  $T_{RM}$  spontaneously generated  
94 retrograde F-actin flow as force-generating module for translocation. Furthermore,  $T_{RM}$  displayed a  
95 highly contractile actomyosin cytoskeleton, leading to continuous bleb formation at the leading  
96 edge. Autonomous cell motility was also observed in lacrimal gland  $T_{RM}$  but not  $T_N$  or small  
97 intestine  $T_{RM}$ , and was strictly dependent on their ability to sense and react to mechanical load of  
98 their microenvironment. Mechanosensing triggered an “evasion reflex”, which elicited cortical  
99 actomyosin contractility through arachidonic acid and intracellular  $Ca^{2+}$  signaling, and correlated  
100 with nuclear deformation in line with the recently uncovered function of the nucleus as  
101 mechanosensor in mammalian and non-mammalian cells (29, 30). Inhibition of mechanosensing  
102 signaling disrupted  $T_{RM}$  tissue scanning and interception of target cells. In sum, our data suggest  
103 that memory T cells lodged in organs with low microbial exposure have co-opted a conserved  
104 mechanosensory module for immunosurveillance, and uncover an instructive role for physical  
105 confinement to elicit dynamic T cell motility. In combination with their preserved chemosensing  
106 capacity, our data identify a multitier strategy for  $T_{RM}$ -mediated tissue surveillance. Such a strategy  
107 bypasses the requirement for elevated constitutive chemokine and adhesion receptor expression  
108 in resting non-barrier tissues, thus preventing unwarranted leukocyte influx.

## 109 Results

110 *SMG T<sub>RM</sub> spontaneously generate retrograde F-actin flow in the absence of chemoattractants and*  
111 *specific adhesions*

112 Our previous *in vivo* and *ex vivo* analysis uncovered high intrinsic SMG CD8<sup>+</sup> T<sub>RM</sub> motility (**Movie**  
113 **1**), which bypasses canonical chemoattractant sensing and adhesion receptor engagement (26).  
114 To generate SMG CD8<sup>+</sup> T<sub>RM</sub> for an in-depth examination of the underlying actomyosin cytoskeleton  
115 regulation, we adoptively transferred congenically marked OT-I TCR tg CD8<sup>+</sup> T cells, which  
116 recognize the ovalbumin (OVA) peptide OVA<sub>257-264</sub> in the context of H-2K<sup>b</sup> (31), into C57BL/6 mice.  
117 One day later, recipient mice were infected with lymphocytic choriomeningitis virus-OVA (LCMV-  
118 OVA), a replication-competent, attenuated LCMV variant encoding OVA as model antigen (32)  
119 (**Fig. 1A**). While rapidly cleared, LCMV-OVA infection results in OT-I expansion and formation of  
120 T<sub>CM</sub> and T<sub>EM</sub> populations in spleen and lymph nodes (LN), and *bona fide* CD103<sup>+</sup> T<sub>RM</sub> in SMG at ≥  
121 30 d p.i. (**Fig. S1A**). Cell sizes were similar between T<sub>N</sub> and endogenous or adoptively transferred  
122 CD8<sup>+</sup> T<sub>EM</sub> and T<sub>RM</sub>, while T<sub>CM</sub> showed a tendency to increased cell sizes (**Fig. S1B**). Similarly,  
123 levels of the F-actin regulators phospho-Cofilin and DOCK2 were not elevated in T<sub>RM</sub> as compared  
124 to other memory subsets, and expression and phosphorylation of ERM proteins, which link cortical  
125 F-actin to the plasma membrane, remained unchanged (**Fig. S1C-F**). In contrast, both endogenous  
126 and adoptively transferred SMG CD8<sup>+</sup> T<sub>RM</sub> contained significantly higher F-actin levels as  
127 compared to other T cell subsets (**Fig. 1B**).

128 We used the F-actin probe LifeAct-GFP to examine steady-state actin cytoskeleton dynamics in  
129 T<sub>RM</sub> (33). We generated LifeAct-GFP<sup>+</sup> SMG OT-I T<sub>RM</sub> as above and compared their cortical actin  
130 cytoskeleton dynamics to LifeAct-GFP<sup>+</sup> T<sub>N</sub> as well-characterized benchmark, using total internal  
131 reflection fluorescence (TIRF) microscopy in an under agarose system (23, 34–36). Under agarose  
132 assays allow to create promigratory conditions in the absence of a directional chemokine gradient,  
133 thus mimicking the random guided walk characteristic of T<sub>N</sub> in lymphoid tissue and the homeostatic  
134 surveillance of T<sub>RM</sub> in SMG (23, 26, 37). Initially, we measured F-actin flow without cellular  
135 translocation by placing T<sub>N</sub> and T<sub>RM</sub> onto “slippery” surfaces passivated with Pluronic<sup>TM</sup> F-127  
136 (pluronic), a nonionic surfactant polyol. This approach permits to quantify cortical F-actin flow  
137 speeds occurring during spontaneous or chemokine-induced F-actin treadmilling. In the absence of

138 chemokines,  $T_N$  contained only sparse and short-lived cortical F-actin dots correlating with their  
 139 unpolarized phenotype (**Fig. 1C and D; Movie 2**). To assess the impact of biochemical stimulation  
 140 on F-actin dynamics, we added CCL19 as ligand for the  $T_N$ -expressed chemokine receptor CCR7.  
 141 CCL19 rapidly induced cortical F-actin filaments that flowed from the leading to the trailing edge  
 142 with speeds of  $14.5 \pm 8.2 \mu\text{m}/\text{min}$  (mean  $\pm$  SD; **Fig. 1C and D**). This resulted in a “running on the  
 143 spot”-phenotype on pluronic-passivated surfaces (**Movie 2**). When CCL19-stimulated  $T_N$  were  
 144 plated on ICAM-1-coated plates, retrograde F-actin flow was converted into fast chemokinetic cell  
 145 movement by force-coupling of LFA-1 to ICAM-1 as described (23) (**Fig. 1C and D; Movie 2**). This  
 146 was accompanied by the stalling of net rearward F-actin flow, with LifeAct-GFP<sup>+</sup> F-actin becoming  
 147 stationary in relation to the substrate (**Fig. 1D**).  
 148 In contrast to  $T_N$ , LifeAct-GFP<sup>+</sup> SMG  $T_{RM}$  plated on pluronic-passivated surfaces showed intrinsic  
 149 cortical F-actin treadmilling from the front to the rear with speeds of  $9.7 \pm 6.8 \mu\text{m}/\text{min}$  (**Fig. 1C and**  
 150 **D**), resulting in a polarized phenotype. This was accompanied by frequent F-actin protrusion  
 151 formation at the leading edge (**Movie 3**). Thus, SMG  $T_{RM}$  not only contain more total F-actin but  
 152 also exhibit a continuous front-to-back flow of F-actin filaments even in the absence of biochemical  
 153 cues (i.e., chemokines). To assess the impact of chemokines on F-actin flow, we added CXCL10,  
 154 the ligand for the  $T_{RM}$ -expressed chemokine receptor CXCR3, as these cells do not express CCR7.  
 155 While the speed of retrograde cortical F-actin flow was accelerated to  $12.8 \pm 8.5 \mu\text{m}/\text{min}$  upon  
 156 CXCL10 exposure, the increase was lower than for chemokine-stimulated  $T_N$  (**Fig. 1C and D;**  
 157 **Movie 3**). Front-to-back F-actin flow stalled when  $T_{RM}$  were placed on lipid-free human serum  
 158 albumin (HSA), which provides sufficient friction to generate traction force for cell translocation, in  
 159 the absence of specific adhesive interactions (**Fig. 1C and D; Movie 3**) (26). In addition, we  
 160 observed occasional forward movement of F-actin filaments at the trailing edge (**Fig. 1C, dashed**  
 161 **line**). This observation is indicative of a highly contractile uropod, which drags F-actin filaments  
 162 towards the leading edge (38). In sum,  $T_{RM}$  use retrograde cortical F-actin flow for translocation  
 163 akin to the cortical flow-force transmission model described for motile  $T_N$  (23, 39). Unlike  $T_N$ ,  
 164 cortical F-actin flow in  $T_{RM}$  is induced spontaneously, i.e., in the absence of external  
 165 chemoattractants. Nonetheless, our data confirm that SMG  $T_{RM}$  remain responsive to CXCL10.  
 166 This is in line with previous observations that CXCR3<sup>-/-</sup>  $T_{RM}$  do not accumulate around tissue

macrophage clusters *in vivo* despite scanning salivary gland parenchyma with speeds comparable to wild type  $T_{RM}$  (26).

*Morphometric analysis uncovers high protrusion formation in spontaneously migrating SMG  $T_{RM}$*

We compared the amoeboid motility modes of  $T_N$  and  $T_{RM}$  in more detail by examining displacement parameters in combination with a morphometric (i.e., cell shape) analysis. To this end, we used wide-field fluorescence microscopy of T cells under agarose (without pluronic passivation) and determined cell speeds, meandering index, cell area and circularity, as well as numbers and sizes of leading edge protrusions using a customized analysis pipeline (**Fig. 1E and Fig. S2**). We first compared  $T_N$  motility on HSA without CCL19 as non-migratory substrate to ICAM-1 + CCL19-coated plates to mirror conditions used for F-actin flow measurements (23). In agreement with F-actin dynamics identified by TIRF microscopy (**Fig. 1C**),  $T_N$  converted from a non-motile state with rounded cell morphology in the absence of chemokines and adhesive ligands to a polarized phenotype with high speeds and directionality when ICAM-1 and CCL19 were present (from  $1.2 \pm 0.5 \mu\text{m}/\text{min}$  to  $13.1 \pm 4.8 \mu\text{m}/\text{min}$ ; **Fig. 1F and G; Movie 4**).  $T_N$  speeds closely matched CCL19-triggered rearward F-actin flow speeds under slippery conditions (**Fig. 1G**), suggesting that force coupling efficiently converts F-actin flow into forward movement. Irrespective of the presence or absence of CCL19,  $T_N$  formed very few protrusions (**Fig. 1G, bottom middle panel**).

In line with TIRF measurements,  $T_{RM}$  acquired a spread and polarized shape with numerous protrusions and spontaneously moved on HSA-coated plates, in the absence of chemokines and specific adhesive substrates (**Fig. 1F and G**). We then examined the impact of chemokine addition in presence of ICAM-1 coating to recreate similar promigratory conditions as used for  $T_N$ . Whereas ligands for the  $T_{RM}$ -expressed chemokine receptors CXCR3 and CXCR4 together with ICAM-1 augmented SMG  $T_{RM}$  speeds (from  $6.7 \pm 3.0 \mu\text{m}/\text{min}$  to  $10.5 \pm 3.1 \mu\text{m}/\text{min}$ ), the increase was less pronounced as in  $T_N$  (**Fig. 1G and Movie 5**). Furthermore, chemokine exposure did not increase  $T_{RM}$  directionality (as assessed by the meandering index), in contrast to  $T_N$  (**Fig. 1G**). Instead, chemokines reduced protrusion formation in  $T_{RM}$  (**Fig. 1G**). Taken together, autonomously moving  $T_{RM}$  display a protrusion-rich amoeboid migration phenotype, which is distinct from the well-

characterized  $T_N$  mode (23). Our data are in line with a model where protrusion formation does not translate into fast leukocyte motility (38), but is instead driven by retrograde F-actin flow and force coupling to substrate (23, 39).

#### *Constitutive DOCK2-Rac-Arp2/3 signaling is required for autonomous SMG $T_{RM}$ motility*

Since retrograde F-actin flow can be generated by F-actin polymerization at the leading edge and/or by Rho-mediated contraction of the F-actin network (22, 40–42), we used under agarose assays to explore the roles for Rac and Cdc42 as major drivers of Arp2/3-mediated F-actin generation at the leading edge (43)(**Fig. S3A**). Reflecting the accumulation of the Rac GEF DOCK2 at the leading edge of migrating  $T_{RM}$  (**Fig. S3B**), the DOCK2 inhibitor CPYPP (44) and CK666, an inhibitor of the DOCK2-Rac downstream target Arp2/3 (45), decreased speeds, meandering index and protrusion formation in SMG  $T_{RM}$ , with a concomitant increase in circularity and a decrease in cell area (**Fig. S3C and D; Movie 6**). Similarly, inhibition of Rac1 using the W56 peptide inhibited autonomous  $T_{RM}$  motility (**Fig. S3E and F**). In contrast, the Cdc42 inhibitor ML141 did not alter  $T_{RM}$  speeds and circularity, although it caused a trend to a lower meandering index and a minor decrease in cellular area and average protrusion size (**Fig. S3C and D**). To corroborate the roles for Rac- versus Cdc42-driven  $T_{RM}$  motility *in vivo*, we adoptively transferred WT tdTom<sup>+</sup> and GFP<sup>+</sup> OT-I T cells lacking DOCK2 or the Cdc42 GEF DOCK8 into C57BL/6 recipients one day prior to infection with LCMV-OVA. Although DOCK2 deficiency impairs T cell accumulation in non-lymphoid tissues (46), we were able to identify occasional DOCK2<sup>-/-</sup>  $T_{RM}$  at > 30 days p.i. within SMG. Intravital imaging confirmed strongly reduced cell speeds and directionality in the absence of DOCK2 as compared to WT  $T_{RM}$  (**Fig. S3G and H; Movie 7**). DOCK8 has previously been shown to mediate T cell migration in skin (47). In contrast, DOCK8<sup>-/-</sup> SMG  $T_{RM}$  moved with comparable speeds as WT  $T_{RM}$ , with only a minor reduction in directionality (**Fig. S3I**). These data support a central role for leading edge DOCK2-Rac-Arp2/3-driven F-actin polymerization for SMG  $T_{RM}$ -mediated tissue surveillance.

#### *SMG $T_{RM}$ possess high constitutive actomyosin contractility*

224 We next examined the role of actomyosin contractility for spontaneous SMG T<sub>RM</sub> motility. Non-  
 225 muscle Myosin IIA (MYH9)-mediated contractility of F-actin filaments supports amoeboid cell  
 226 motility by pulling F-actin filaments towards the trailing edge and by generating force to push the  
 227 nucleus as the biggest organelle through narrow pores (48). Using a reporter line expressing GFP-  
 228 tagged Myosin IIA under the endogenous *Myh9* promoter (49), we observed significantly higher  
 229 MYH9-GFP levels in SMG OT-I T<sub>RM</sub> as compared to T<sub>CM</sub> and T<sub>EM</sub>, suggesting a high baseline  
 230 contractility (**Fig. 2A**). In under agarose assays, MYH9-GFP accumulated mostly at the trailing  
 231 edge of migrating SMG T<sub>RM</sub> (**Fig. 2B; Movie 8**), consistent with local F-actin contractions observed  
 232 in TIRF imaging (**Fig. 1C**). MYH9-GFP also accumulated in protrusions of the leading edge,  
 233 followed by their subsequent retraction (**Fig. 2B**). This observation points to a dual role for Myosin  
 234 IIA activity: on the one hand, to contract the uropod, and second, to retract protrusions that are not  
 235 aligned with the migratory path, as described for neutrophils (50). In line with elevated MYH9  
 236 expression, SMG T<sub>RM</sub> contained two to three times higher pMLC levels as compared to T<sub>CM</sub> and  
 237 T<sub>EM</sub> (**Fig. 2C and D**).  
 238 We next attempted to genetically assess MYH9 function for SMG T<sub>RM</sub> scanning, but failed to obtain  
 239 MYH9-deficient peripheral T cells in a CD4-Cre x MYH9<sup>fl/fl</sup> line (**Fig. S4A**). Similarly, Cas9-  
 240 mediated MYH9 depletion resulted in defective OT-I T cell expansion following viral infection, in  
 241 line with its role in cytokinesis (51) (**Fig. S4B and C**). We therefore performed under agarose  
 242 assays in presence of selected inhibitors of the MLC phosphorylation cascade (**Fig. 2E**). Direct  
 243 inhibition of Rho using Rhosin decreased SMG T<sub>RM</sub> speeds and protrusion sizes (**Fig. S5A and B**).  
 244 We next evaluated its downstream effectors, myosin light chain kinase (MLCK) and Rho-  
 245 associated coiled-coil kinase (ROCK), both of which regulate pMLC levels. MLCK inhibition slightly  
 246 reduced T<sub>RM</sub> speeds (from  $7.1 \pm 3.7$  to  $5.4 \pm 3.0$   $\mu\text{m}/\text{min}$ ; mean  $\pm$  SD) but did not significantly alter  
 247 directionality, cell shape and area, or protrusion formation (**Fig. 2F and G; Movie 9**). In contrast,  
 248 the ROCK inhibitor Y-27632 caused cell rounding and a substantial decrease in speeds to  $0.7 \pm$   
 249  $2.7$   $\mu\text{m}/\text{min}$ , as well as low directionality and protrusion formation (**Fig. 2F and G; Movie 9**).  
 250 Furthermore, Y-27632 blocked topography-driven T<sub>RM</sub> motility on pluronic-passivated surfaces  
 251 (**Fig. S5C and D**), as well as SMG T<sub>RM</sub> surveillance *in situ* as assessed by intravital imaging (**Fig.**  
 252 **S5E**). Since Rho-GTP activates nucleation factors of the formin/mDia family, we performed under

253 agarose assays in presence of the Formin Homology 2 domain inhibitor SMIFH2. We observed  
254 decreased  $T_{RM}$  speeds, directionality, protrusion formation and cell area in presence of this  
255 inhibitor (**Fig. S5F and G**). As caveat, SMIFH2 has been reported to affect additional factors  
256 including MYH9 (52, 53). In sum, SMG  $T_{RM}$  possess high intrinsic actomyosin contractility, which is  
257 required for inherent motility and organ surveillance.

258  
259  *$T_{RM}$  form blebs at the leading edge during 2D and 3D space exploration*

260 High baseline actomyosin contractility leads to increased intracellular hydrostatic pressure that can  
261 cause bleb formation. Blebs are short-lived membrane protrusions, which form after detachment  
262 from the underlying cortical F-actin layer and can contribute to cell motility (16). Blebs were  
263 recently described in sphingosine-1-phosphate-stimulated  $T_N$  (54) but have never been observed  
264 in resting, unmanipulated leukocytes (55). We assessed whether high actomyosin contractility in  
265 SMG  $T_{RM}$  resulted in bleb formation during migration. To unequivocally distinguish F-actin-filled  
266 protrusions from blebs, we generated LifeAct-GFP x mT/mG OT-I T cells, in which F-actin and  
267 plasma membrane are tagged with GFP and tdTom, respectively (**Fig. 2H**). We transferred LifeAct-  
268 GFP x mT/mG OT-I into recipient C57BL/6 mice, followed by LCMV-OVA infection and sorting of  
269 SMG  $T_{RM}$  in the memory phase. High frame-rate *in vitro* imaging confirmed the presence of two  
270 types of leading edge protrusions: F-actin-filled protrusions and membrane blebs, which were  
271 rapidly ( $< 1$  s) filled with F-actin (**Fig. 2I; Movie 10**). This correlated with quick accumulation of  
272 DOCK2 into blebs (**Movie 10**). We did not find evidence for formation of thin lamellipodia  
273 characteristic of lymphoblasts migrating on adhesive 2D surfaces (56), perhaps owing to the low  
274 adhesiveness of HSA and the substantially lower amount of cytoplasm in resting versus activated  
275 T cells (57). Both F-actin-filled protrusions and blebs were short-lived, since they were either  
276 followed by the translocation of the cell body or by retraction. Bleb formation was restricted to the  
277 leading edge of motile  $T_{RM}$  and also seen in presence of a pan-caspase inhibitor to prevent  
278 apoptotic cell death (not shown). Residual bleb formation was also observed in SMG  $T_{RM}$  treated  
279 with the DOCK2 inhibitor CPYPP (not shown). However, this did not suffice to promote cell  
280 translocation, in line with the requirement for Rac signaling to promote migration (**Fig. S3**). Finally,  
281 we also detected F-actin-filled protrusion and rapid bleb formation that bulge out into the

extracellular space at the front of  $T_{RM}$  moving in 3D collagen matrices, occasionally followed by the bulky nucleus (**Fig. 2I; Movie 10**). Bleb-supported migration is therefore suited to rapidly explore the available space in front of the cell's leading edge. Alternatively or in addition, blebs might contribute to motility and cell survival (17, 58). In sum, motile  $T_{RM}$  and  $T_N$  differ in two key features: first, rearward F-actin flow in  $T_{RM}$  is generated even without external guidance cues. Second,  $T_{RM}$  possess high intrinsic actomyosin contractility correlating with formation of blebs and F-actin-filled protrusions.

289

#### *Exocrine gland $T_{RM}$ use mechanosensing to trigger polarization and motility*

We next explored the cellular and molecular mechanism underlying autonomous SMG  $T_{RM}$  motility. Previous studies have shown that activated T cells migrate rapidly on 2D surfaces without confinement (59). Furthermore, non-attached leukocytes can use rearward F-actin treadmilling or Myosin II-dependent membrane flow for fast translocation (60, 61). To test whether this also applies to SMG  $T_{RM}$ , we examined their migration dynamics on 2D surfaces without agarose overlay, anticipating that these highly contractile cells would continue to display a polarized phenotype and motility (**Fig. 3A**). However, most  $T_{RM}$  lost their polarized cell shape and created significantly fewer protrusions on 2D surfaces as spatially confined cells did (**Fig. 3B-D**). As a result,  $T_{RM}$  displacement was essentially abolished under these conditions (**Fig. 3C and D**). Thus,  $T_{RM}$  need spatial confinement to acquire a polarized phenotype and for translocation.

To further delineate the relationship between spatial confinement, cell morphometry and autonomous motility, we exposed SMG  $T_{RM}$  to distinct mechanical loads. We adjusted the agarose concentration from 0.5% (corresponding to a Young's modulus of 2.9 kPa) to 1% (9.8 kPa) as described (23). We found that  $T_{RM}$  responded to the degree of mechanical load with changes in cell shape, protrusion formation and motility parameters. When exposed to higher mechanical load (1% agarose),  $T_{RM}$  slowed down, moved less directionally, were less polarized and formed fewer protrusion. These data are consistent with a model where the forces required to lift agarose for protrusion formation and cell motility increase under high mechanical load, resulting in reduced cell migration. We then analyzed  $T_{RM}$  motility exposed to 0.125% and 0.25% agarose, assuming that reduction of the environmental resistance to deformation facilitates cell motility. Remarkably, we



311 found that under conditions of reduced mechanical load,  $T_{RM}$  moved more slowly, were more  
312 spherical and formed fewer and smaller protrusions as with 0.5% agarose (**Fig. 3E and F**). Thus,  
313  $T_{RM}$  react to the degree of confinement using a mechanosensing module.  
314 Next, we examined whether mechanosensing was a property shared with  $T_{RM}$  from other internal  
315 organs. To address this point, we isolated  $T_{RM}$  from another exocrine gland, the lacrimal gland  
316 (LG), or from the epithelial barrier of the small intestine (SI) after LCMV-OVA infection. In under  
317 agarose assays, LG but not SI  $T_{RM}$  displayed confinement-induced motility akin to SMG  $T_{RM}$  (**Fig.**  
318 **3G and H**). In combination with the observation that epidermal  $T_{RM}$  do not respond to physical  
319 confinement (26), these data suggest that exocrine gland but not skin or gut  $T_{RM}$  have acquired the  
320 ability to mechanosense their environment, i.e., to measure and respond to mechanical load with  
321 gradual induction of polarity and cell motility.

322

323 *Confinement-induced  $T_{RM}$  motility requires nuclear mechanosensing-triggered signaling pathways*  
324 We explored the mechanism underlying cellular proprioception, which translates mechanical cell  
325 deformation into adaptive cytoskeletal dynamics. We excluded classical integrin-based  
326 mechanotransduction, since we observed  $T_{RM}$  polarization in the absence of specific integrin  
327 ligands, as well as on pluronic-passivated surfaces containing PS beads (**Fig. S5C**). The cortical  
328 actomyosin cytoskeleton itself can act as mechanosensor, but its rapid turnover ( $> 1$  min) limits  
329 deformation sensing (62). Similarly, constant vesicle trafficking at the plasma membrane renders a  
330 role for stretch-induced mechanosensing less likely (63). In turn, induction of SMG  $T_{RM}$  polarity and  
331 motility by mechanical load was highly reminiscent of the “evasion reflex” shown by various  
332 mammalian and non-mammalian cell types subjected to spatial confinement. These cells use their  
333 nuclei to measure absolute environmental dimensions (29, 30). According to this “nuclear ruler”  
334 model, confinement-induced mechanical unfolding of the nuclear envelope (NE) leads to activation  
335 of  $Ca^{2+}$ -dependent cytosolic phospholipase A2 (PLA2) enzymes, which act as NE stretch sensors  
336 (63). The resulting production of arachidonic acid (AA) leads to membrane recruitment and  
337 activation of MYH9, which in turn stimulates sustained actomyosin contraction, bleb formation and  
338 motility (29, 30), hallmarks of SMG  $T_{RM}$  migration observed here.

339 To examine whether SMG  $T_{RM}$  had co-opted the nucleus as mechanosensory organelle for  
340 spontaneous migration under confinement, we analyzed nuclear shape under 0.5% agarose  
341 confinement. These data confirmed that  $T_{RM}$  nuclei became stretched as reflected by increased  
342 maximal cross-section area and lower heights (**Fig. 4A and B**). To directly establish a link between  
343 mechanical cell deformation, cell morphometry and motility, we used confinement chambers with  
344 defined heights to induce nuclear compression without interfering with protrusion formation (**Fig.**  
345 **4C**). At 7  $\mu\text{m}$  chamber height,  $T_{RM}$  became trapped without substantial nuclear compression. Under  
346 these conditions,  $T_{RM}$  remained immotile and round, forming only sparse protrusions (**Fig. 4D**). In  
347 contrast,  $T_{RM}$  placed in 4  $\mu\text{m}$  height chambers acquired a highly polarized cell shape with multiple  
348 protrusions that correlated with the induction of spontaneous motility (**Fig. 4D; Movie 11**). To  
349 examine whether mechanosensing-triggered motility can also be induced in other T cell subsets at  
350 a distinct confinement threshold, we placed SMG  $T_{RM}$  or  $T_N$  in 2-and 4  $\mu\text{m}$ -high chambers. In  
351 contrast to  $T_{RM}$ ,  $T_N$  did not display spontaneous motility at 4  $\mu\text{m}$  confinement, while both cell  
352 populations failed to migrate under 2  $\mu\text{m}$  confinement, accompanied by signs of cell death (**Fig. S6**  
353 **A and B**). Thus, in the experimental conditions used here, we could not induce  $T_{RM}$ -like motility in  
354  $T_N$  isolated from lymphoid tissue.

355 To further corroborate the link between nuclear deformation and confinement-induced  $T_{RM}$  motility,  
356 we used the AA analog AACOCF3 as inhibitor of PLA2 and other AA-producing enzymes (**Fig. 4E**)  
357 (29). In under agarose assays, AACOCF3 treatment led to decreased  $T_{RM}$  speeds, as well as  
358 reduced directionality and number and size of leading edge protrusions (**Fig. 4F and G; Movie**  
359 **12**). Addition of excess AA to AACOCF3-treated  $T_{RM}$  rescued SMG  $T_{RM}$  speeds, cell spreading,  
360 and protrusion sizes. Of note, AA-treated  $T_{RM}$  cells frequently changed direction, resulting in a low  
361 meandering index (**Fig. 4F and G; Movie 12**). These data suggest that while SMG  $T_{RM}$  are able to  
362 respond to external AA, this treatment affects the preservation of stable polarity. We examined  
363 whether other T cell populations responded similarly to AA stimulation. While addition of AA slightly  
364 increased chemokinetic  $T_N$  speeds (from 0.6 to 1.5  $\mu\text{m}/\text{min}$ ), this effect was much lower as  
365 compared to the impact of CCL21, suggesting that AA is not sufficient to induce robust motility in  
366 these cells. Along the same line, AACOCF3 treatment did not impair CCL21-induced  $T_N$  motility,  
367 whereas it partially reduced CXCL10-induced  $T_{RM}$  speeds and directionality (**Fig. S6C and D**).

368 In addition to AA production, nuclear mechanosensing requires generation of an intracellular  $\text{Ca}^{2+}$   
 369 flux, whereas extracellular  $\text{Ca}^{2+}$  is not required (29, 30). To address the role for intracellular  $\text{Ca}^{2+}$   
 370 sensing, we blocked intracellular  $\text{Ca}^{2+}$  by BAPTA-AM. In parallel, we added 2APB to inhibit stretch-  
 371 sensitive channels such as inositol triphosphate receptors (InsP3R), which liberate  $\text{Ca}^{2+}$  from NE  
 372 and perinuclear endoplasmatic reticulum (ER) membranes. Both inhibitors resulted in a strongly  
 373 decreased  $T_{\text{RM}}$  speeds, directionality, cell polarization and protrusion formation (**Fig. 4H and I;**  
 374 **Movie 13**). Taken together, confinement-induced SMG  $T_{\text{RM}}$  migration is susceptible to inhibitors of  
 375 the nuclear mechanosensing module (29, 30).

376 Next, we analyzed whether  $T_{\text{RM}}$  expressed candidate factors involved in nuclear mechanosensing  
 377 (**Fig. 4E**). The ubiquitously expressed family member cPLA2a (encoded by *Pla2g4a*) has been  
 378 implied in regulating the mechanosensitive response in DCs and other cell types (29, 30, 63).  
 379 However, mining the Immgen database (<https://www.immgen.org/>) showed low to absent *Pla2g4a*  
 380 expression in T cells except for double-negative thymocytes, which we confirmed by qPCR  
 381 analysis (**Fig. S7A and B**). Similarly, single cell RNA sequence analysis of SMG  $T_{\text{RM}}$  failed to  
 382 detect *Pla2g4a* expression (not shown). For increased sensitivity, we performed a "NanoString"  
 383 multiplex gene expression analysis of factors potentially involved the mechanosensitive response  
 384 by comparing sorted  $T_{\text{N}}$ ,  $T_{\text{CM}}$ ,  $T_{\text{EM}}$  and SMG  $T_{\text{RM}}$  OT-I T cells. First, we validated the sorting  
 385 strategy by confirming subset-specific marker detection (**Fig. S7C**). While this sensitive approach  
 386 corroborated low to absent *Pla2g4a* expression in T cells, we detected expression of *Pla2g4b*,  
 387 *Pla2g10*, *Pla2g12a* and *Pla2g15* in  $T_{\text{RM}}$  (**Fig. S7D**). SMG  $T_{\text{RM}}$  also expressed stretch-activated  
 388 InsP3Rs, which are involved in intracellular  $\text{Ca}^{2+}$  release upon nuclear compression (**Fig. S7E**) (29,  
 389 64). We did not detect noticeable differences between memory T cell subset expression of factors  
 390 regulating nuclear envelope structure including lamin A/C, lamin B receptor, and emerin as well as  
 391 members of the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex Sun1/2 and Nestrins  
 392 1-4 (**Fig. S7F and G**). Taken together,  $T_{\text{RM}}$  express several  $\text{Ca}^{2+}$  channels and PLA2 isoforms, as  
 393 well as other enzymes capable of producing AA such as phospholipase B (not shown).

394  
 395 *Mechanosensing-induced  $T_{\text{RM}}$  motility enhances target cell interception*

396 We designed an *in vitro* system to examine the impact of T<sub>RM</sub> mechanosensing on target cell  
397 encounter as a simplified tissue surveillance test. We placed SMG T<sub>RM</sub> with a majority of unpulsed  
398 B cells spiked with rare cognate pMHC-pulsed, fluorescently labeled B cells in under agarose  
399 confinement (**Fig. 5A**). In this system, T<sub>RM</sub> need to actively migrate to identify dispersed target cells  
400 among an excess of bystander cells. Indeed, T<sub>RM</sub> were actively scanning B cells for presence of  
401 cognate pMHC (**Movie 14**). Within the observation period, almost half of the control T<sub>RM</sub> (47%)  
402 were able to identify and engage with at least one target cell during the observation period, with  
403 8% of T<sub>RM</sub> interacting with four or more targets (**Fig. 5B and C**). Many interactions were short-lived  
404 and resulted in cell death as assessed by dye leakage (**Movie 14**). Addition of the PLA2 inhibitor  
405 AACOCF3 disrupted the “search and destroy” pattern (**Fig. 5B**), with only 32% and 2% of T<sub>RM</sub>  
406 engaged with more than one and a maximum of four targets, respectively (**Fig. 5C**). In sum,  
407 confinement-induced random motility enhances the ability for T<sub>RM</sub> to efficiently track and eliminate  
408 dispersed target cells.

#### 409 410 *In vivo interference with mechanosensing impairs SMG T<sub>RM</sub> surveillance*

411 We set out to expand our *in vitro* observations to tissue surveillance *in vivo*. Confocal analysis  
412 confirmed nuclear deformation occurring in SMG T<sub>RM</sub> within dense secretory epithelium-rich tissue  
413 (**Fig. 6A**). To examine nuclear mechanosensing-triggered pathways during homeostatic SMG  
414 surveillance, we used 2PM to quantify baseline OT-I T<sub>RM</sub> motility parameters in LCMV-OVA-  
415 immunized SMG before overlaying 20 or 50  $\mu$ M BAPTA-AM on the SMG preparation for 20 min  
416 and recording T<sub>RM</sub> motility for additional 1-4 h (**Fig. 6B; Movie 15**). BAPTA-AM has been reported  
417 to accumulate efficiently in cells *in vivo* (65). Accordingly, the short BAPTA-AM superfusion caused  
418 a dose-dependent decrease in SMG T<sub>RM</sub> speeds and directionality (**Fig. 6C-F**), with a concomitant  
419 increase in arrest coefficients and sphericity (**Fig. 6F and G**). These observations are consistent  
420 with the pronounced inhibition of T<sub>RM</sub> migration by intracellular Ca<sup>2+</sup> chelation in under agarose  
421 assays (**Fig. 4H and I**).

422 Finally, we examined whether mechanosensing contributes to SMG T<sub>RM</sub> surveillance in response  
423 to a local virus rechallenge. We administered an attenuated murine cytomegalovirus (MCMV)-3D-  
424  $\Delta$ vRAP strain expressing mCherry and the OVA<sub>257-264</sub> peptide epitope into SMG via the Wharton's

duct of LCMV-OVA-immunized mice in the memory phase, as described (26). Recipient mice were subsequently treated with DMSO or AACOCF3 for 68 h post MCMV infection (**Fig. 6H**). We chose AACOCF3 over BAPTA-AM to avoid an impact on  $T_{RM}$  function resulting from impaired intracellular  $Ca^{2+}$  flux. Intravital imaging confirmed that immediately after AACOCF3 treatment of LCMV-OVA-memory mice, the SMG  $T_{RM}$  scanning behavior was disrupted as measured by a drop in directionality, although speeds were not significantly affected in the conditions used here (**Fig. S8A and B**). This may reflect the weaker *in vitro* inhibition by AACOCF3 as compared to  $Ca^{2+}$  chelators (**Fig. 4F**). Following MCMV infection via the Wharton's duct, we administered anti- $\alpha 4$  and  $\alpha_L$  (LFA-1)-blocking mAbs to prevent recruitment of circulating T cells without affecting interstitial  $T_{RM}$  motility (26). Neither administration of AACOCF3 over 3 d alone or in combination with anti- $\alpha 4$  and LFA-1 blocking mAbs had a significant effect on total  $T_{RM}$  numbers or their CD69 and CD103 expression (**Fig. S8C and D**). In control experiments, MCMV-3D- $\Delta v$ RAP infection into one SMG lobe did not yield a significant increase in  $T_{RM}$  numbers as compared to uninfected contralateral lobes (**Fig. S8E and F**), irrespective of treatment with anti- $\alpha 4$  and LFA-1 integrin mAbs or the lymphocyte-sequestering drug FTY720 (**Fig. S8F and G**). These data suggested no or only limited local proliferation of SMG  $T_{RM}$  or T cell recruitment during re-challenge with the attenuated MCMV strain used here. In accordance, we observed only few mCherry<sup>+</sup> MCMV-infected cells in control- and AACOCF3-treated SMG sections at 68 h p.i. (**Fig. S8H**), in line with the key role for tissue-resident macrophages for clearance of infected cells (26). Consistent with these observations, a histological analysis of MCMV-challenged SMG sections on day 3 p.i. showed comparable numbers of SMG  $T_{RM}$  in control- and AACOCF3-treated recipients (**Fig. 6J and I**). In contrast, when we examined  $T_{RM}$  distribution as a readout for inflammation-induced T cell accumulation, we observed an average of  $10.5 \pm 4.6$   $T_{RM}$  clusters/section (mean  $\pm$  SEM; median 4.8) in control-treated SMG, with  $T_{RM}$  accumulating both in EpCAM<sup>high</sup> epithelial tubes and EpCAM<sup>low</sup> acini (**Fig. 6I and K**). In contrast,  $T_{RM}$  clustering in infected SMG was substantially reduced to  $1.9 \pm 1.9$  clusters (median 1.3) in AACOCF3-treated recipients (**Fig. 6I and K**). Taken together, these data support a role for mechanosensing for  $T_{RM}$  tissue surveillance of exocrine glands as a complementary mechanism to canonical motility driven by biochemical cues (**Fig. 6L**) (29, 30, 66, 67).

## 453 **Discussion**

454 CD8<sup>+</sup> T<sub>RM</sub> surveille organs with diverse tissue architecture, cellular and extracellular matrix  
455 composition and degrees of microbial exposure. Conceivably, organ surveillance is accomplished  
456 by local adaptations of their patrolling modus to enable efficient cell scanning and interception of  
457 re-emerging viral infections. In epithelial barriers that are constitutively exposed to microbes,  
458 chemokines and integrin ligands contribute to T<sub>RM</sub> surveillance (6–12). Here, we report that  
459 exocrine gland T<sub>RM</sub> possess the capacity of spontaneous F-actin treadmilling, which endows them  
460 with an internal force generation module that bypasses the requirement for chemoattractant and  
461 adhesion receptor sensing. Instead, a mechanosensing module assists these cells to measure the  
462 degree of confinement-induced mechanical load. This module is coupled to a promigratory  
463 response and is susceptible to inhibitors of the nuclear mechano-gauge, implying a non-genetic  
464 function of the nucleus in this process. Thus, in these non-barrier organs with low constitutive  
465 chemokine expression (27), memory T cell subsets are equipped to sense and react to the  
466 physical properties of their tissue of residence, extracting promigratory cues from spatial  
467 confinement for baseline surveillance. At the same time, they retain their chemosensing capacity to  
468 complement their protective function during infection, suggesting a multitiered surveillance  
469 strategy.

470 Amoeboid cell migration is based on continuous polymerization of F-actin at the leading edge and  
471 contraction of F-actin filaments by myosin motors at the trailing edge of the cell (48). Both  
472 processes contribute to the generation of a net retrograde F-actin flow, which amoeboid cells  
473 exploit to generate forward locomotion via mechanical coupling to a substrate or liquid. Depending  
474 on the cell type examined, amoeboid migration spans a continuum from mostly Rho-driven  
475 actomyosin contractility-driven (as in some DCs) to mostly Rac-driven motility lacking protrusions  
476 (as in T<sub>N</sub>) (23, 42). Our data suggest that SMG T<sub>RM</sub> acquire a blend of these migration modes,  
477 presumably as an adaptation to the confined microenvironment of exocrine glands (26). Despite  
478 these adjustments, a DOCK2-Rac-Arp2/3 signaling axis is preserved in T<sub>N</sub> and T<sub>RM</sub>, suggesting a  
479 similar molecular wiring of their basic force-generating module in both cell subsets. While  
480 chemokine receptors create mechanical force by activating the DOCK2-Rac-Arp2/3 module in T<sub>N</sub>,  
481 it is currently not known how DOCK2-driven F-actin treadmilling is regulated in T<sub>RM</sub>. Conceivably, a

482 global increase in expression of proteins associated with small GTPase signaling or a decreased  
 483 expression of negative regulators of this pathway might facilitate spontaneous F-actin formation.  
 484 As example, F-actin filament density grows with the square of actin nucleation-promoting factor  
 485 membrane density (68). At the same time,  $T_{RM}$  are characterized by increased expression of RGS1  
 486 and RGS2, negative regulators of chemoattractant receptor signaling (69). This may explain the  
 487 limited impact of chemokine addition to  $T_{RM}$  locomotion as compared to  $T_N$ . Nonetheless, the  
 488 residual capacity of  $T_{RM}$  to respond to chemoattractants suffices for their accumulation at spots of  
 489 viral reemergence (8, 26).

490 Our data further expose that mechanical load suffices to trigger exocrine gland  $T_{RM}$  polarization  
 491 and motility, accompanied by increased cortical actomyosin contractility. Mechanosensing is  
 492 increasingly acknowledged to play a central role in the immune system (70–73). On a molecular  
 493 level, T cells use their TCR as mechanosensitive receptor to gauge pMHC affinity and for target  
 494 cell elimination, in a process called mechanosurveillance (74, 75). In the innate immune system,  
 495 mechanical cues detected by Piezo1 ion channels in macrophages contribute to lung inflammation  
 496 (76), and subsets of spleen DCs use adhesion GPCR as cues for proper positioning close to  
 497 venous sinusoids (77). The influence of physical properties on leukocyte migration in complex  
 498 environments is also well documented (5, 16, 17, 19, 70, 78, 79). In most cases, physical  
 499 constraints are typically considered barriers to leukocyte dissemination, as is the case for  
 500 basement membranes separating endothelial and epithelial cell layers from the interstitium (80). In  
 501 contrast, we show here that exocrine gland  $T_{RM}$  respond to intermediate levels of confinement-  
 502 induced mechanical load with vigorous motility that required high Myosin IIA-driven contractility.  
 503 Thus, while confinement is often associated with impaired motility, exocrine gland  $T_{RM}$  exploit local  
 504 tissue properties to transform mechanical shape deformations into cytoskeletal rearrangements.  
 505 Our data further show that  $T_{RM}$  mechanosensing is susceptible to pharmacological inhibitors of  
 506 signaling pathways induced by nuclear compression. Until recently, the nucleus has been mainly  
 507 considered as a passive storage for genetic information. Furthermore, as the cell's biggest  
 508 organelle, the nucleus constitutes a major obstacle to cellular passage through constricted spaces  
 509 (81). Yet, recent findings in DC and other leukocytes have uncovered a central role for the nucleus  
 510 in selecting the migratory path by determining permissive pore sizes (82). In keeping with this, the

511 nucleus also serves as central element for cellular proprioception. Much like humans sense their  
 512 environment through sight, hearing, touch and smell to react adequately, recent studies have  
 513 provided compelling evidence for nuclear deformation and an autonomous contractile response as  
 514 the cellular correlate of a sense of space and pressure (66, 83). To accomplish this feat, the  
 515 nucleus measures absolute dimensions through the stretching of its NE, which beyond a cell-  
 516 specific setpoint triggers an “evasive reflex” via increased cortical contractility and spontaneous  
 517 cell translocation (29, 30). Given its low constitutive membrane trafficking, the quiescent NE is  
 518 particularly suited as low noise detector to convert mechanical perturbations into chemical signals  
 519 as compared to plasma membranes, which display rapid turnover (84). To date, the precise factors  
 520 generating AA and other signals involved in nuclear mechanosensing are not well characterized  
 521 owing to the complex cell-type-specific regulation of lipid metabolism and  $\text{Ca}^{2+}$  channel expression  
 522 (85–87). As example, the cPLA2a isoform, which has been implicated in regulating the contractile  
 523 response in DCs and zebrafish progenitor stem cells (29, 30, 88), is absent or only expressed at  
 524 very low levels in mature T cells. Together with the fact that compensatory mechanisms between  
 525 different isoforms might occur, genetic approaches to disrupt mechanosensing in  $\text{T}_{\text{RM}}$  constitute a  
 526 formidable challenge. Despite these caveats, the combined data describing i) the close correlation  
 527 of mechanical load, nuclear deformation and induction of polarization and motility, and ii) the  
 528 impact of pharmacological inhibitors of the nucleosensing module AACOCF3, BAPTA-AM and  
 529 2APB on cell shape and motility, are coherent with the published nuclear ruler-based  
 530 mechanosensing model (29, 30).

531 While many cell types display a  $\text{Ca}^{2+}$  and PLA2-mediated response upon nuclear disturbance (29,  
 532 30, 63), our data suggest that mechanosensing-driven motility is not a universal feature of all T cell  
 533 subsets, at least not in the experimental conditions applied here. Thus,  $\text{T}_{\text{N}}$ ,  $\text{T}_{\text{CM}}$  and  $\text{T}_{\text{RM}}$  lodged in  
 534 gut and skin epithelium do not spontaneously move when placed under confinement (26). For the  
 535 latter population, this may reflect their greater dependence on  $\text{G}\alpha_{\text{i}}$ -coupled signaling as compared  
 536 to exocrine  $\text{T}_{\text{RM}}$  (8). Local chemokines induced by constant microbial exposure might help to avoid  
 537 accidental egress of epithelial  $\text{T}_{\text{RM}}$  outside the host by restricting them in close vicinity to the  
 538 basement membrane. In turn, mechanosensing-triggered motility for baseline surveillance might be  
 539 preferentially induced in tissues with limited microbial exposure, where steady-state chemokine



540 levels are low (27). This surveillance strategy equips T<sub>RM</sub> with flexibility to surveille multiple organs  
541 with diverse cellular and matrix composition, while retaining responsiveness to inflammation-  
542 triggered local chemokine gradients.

543 As a limitation, despite providing solid evidence for mechanosensing capacities in T<sub>RM</sub> subsets, the  
544 molecular pathways involved in this process remain undefined. Furthermore, the use of  
545 pharmacological inhibitors to interfere with confinement-induced T<sub>RM</sub> motility might affect additional  
546 signaling pathways in these cells, or influence bystander cells in *in vivo* experiments. Along the  
547 same line, the *in vivo* pharmacokinetics of the PLA2 and Ca<sup>2+</sup> flux inhibitors are not well defined,  
548 rendering an assessment of the degree of inhibition after administration difficult. Finally, our study  
549 does not address to which extent mechanosensing is a property shared with other leukocytes,  
550 such as NK cells lodged in exocrine glands.

551 In sum, while is well-established that the transition of T<sub>N</sub> to T<sub>EFF</sub> and memory T cell subsets is  
552 accompanied by changes in the chemoattractant and adhesion receptor repertoire, our data  
553 suggest that these changes do not fully explain the scanning behavior of these cells in distinct  
554 organs. Thus, physical properties of the tissue of residency are integrated by adaptive immune  
555 cells with local biochemical cues for a specific multitier immune surveillance strategy. It is  
556 conceivable that mechanosensing elicits site-specific signaling, epigenetic and metabolic  
557 adaptations in local immune cell populations, encouraging further investigation into the underlying  
558 molecular regulation.

559

## 560 **Materials and Methods**

### 561 *Study design*

562 The aim of this study was to examine the mechanisms underlying intrinsic motility of SMG T<sub>RM</sub>. To  
563 this end, we systemically administered LCMV-OVA and isolated Ag-specific CD8<sup>+</sup> T cells from  
564 SMG and other organs. We applied *ex vivo* migration assays, immunofluorescence, intravital  
565 imaging, gene expression analysis and flow cytometry to compare their migration requirements  
566 with CD8<sup>+</sup> T<sub>N</sub>. Furthermore, we administered pharmacological inhibitors of small GTPase and  
567 nuclear mechanosensing signaling pathways to functional assays. Last, we assessed the role of  
568 the T<sub>RM</sub> mechanosensing module for target finding and cell clustering after viral re-challenge. Mice  
569 or isolated T cells were randomly assigned to experimental groups and analyzed without excluding  
570 outliers, and experimenters were not blinded. The number of independent experiments is indicated  
571 in the figure legend.

572

### 573 *Mice*

574 Tg(TcraTcrb)1100Mjb ("OT-I") TCR transgenic mice (31) were backcrossed to C57BL/6-Tg(CAG-  
575 EGFP)1Osb/J ("GFP<sup>+</sup>") (89), hCD2-dsRed ("dsRed<sup>+</sup>") (90), tdTomato-expressing Ai14 x ZP3  
576 ("tdTom<sup>+</sup>") (91, 92), mT/mG (93) and LifeAct-GFP lines (33). GFP<sup>+</sup> OT-I were further crossed to  
577 CD4-Cre x MYH9<sup>flox/flox</sup> (94), DOCK2<sup>-/-</sup> (40) and DOCK8<sup>-/-</sup> (95) lines and dsRed<sup>+</sup> OT-I to the MYH9-  
578 GFP reporter line (49). DOCK2-GFP were described before (96). All mice were bred at the animal  
579 facility of the University of Fribourg, Switzerland, and were used as lymphocyte donor mice. Six-to-  
580 ten weeks-old male and female sex-matched C57BL/6JRj mice (Janvier, Le Genest-Saint-Isle,  
581 France) were used as recipient mice. All experiments were performed in accordance to federal  
582 animal experimentation regulations and approved by the cantonal committee (FR\_2021\_24,  
583 FR\_2021\_25, FR\_2021\_30).

584

### 585 *T cell transfer and viral infections*

586 CD8<sup>+</sup> T cells were negatively isolated from spleen and peripheral LNs using the EasySep<sup>TM</sup> Mouse  
587 CD8<sup>+</sup> T cell Isolation Kit (Stem Cell Technologies) or the MojoSort Mouse CD8<sup>+</sup> T cell Isolation Kit

588 (BioLegend) according to manufacturer's instructions. OT-I T cells ( $5 \times 10^4$ ) were i.v. transferred  
 589 into recipient mice 24 h before i.p. infection with  $10^5$  pfu LCMV-OVA (32).

590

# 591 *Reagents*

592 Sodium pyruvate (P04-43100), HEPES buffer (P05-01100), minimum essential medium non-  
 593 essential amino acids (MEM NEAA, P08-32100), L-glutamine 200mM (P04-80100) and PenStrep  
 594 (P06-07100) were purchased from PAN Biotech and RPMI 1640 (#21875-034) and Fetal Bovine  
 595 Serum (FBS, 10270-106) were from Gibco. CPYPP (Tocris) was used at 50  $\mu$ M, CK666 (R&D) at  
 596 100  $\mu$ M, ML141 (Tocris) and MLCK inhibitor peptide 18 (Calbiochem) at 20  $\mu$ M, Y27632 (Sigma-  
 597 Aldrich or Hello Bio) at 20  $\mu$ M or 200  $\mu$ g/mouse *in vivo*, AACOCF3 (Tocris or Enzo Life Sciences)  
 598 at 20  $\mu$ M or 300  $\mu$ g/mouse *in vivo*, BAPTA-AM (Cayman Chemical) at 10  $\mu$ M, arachidonic acid  
 599 (Cayman Chemical) at 70  $\mu$ M, 2APB (Tocris) at 100  $\mu$ M, W56/F56 (R&D) at 100  $\mu$ M and Rhosin  
 600 (Sigma-Aldrich) at 10  $\mu$ M.

601

# 602 *Flow cytometry analysis*

603 At indicated time points, spleens and LNs were harvested and organs were passed through cell  
 604 strainers (70  $\mu$ m; Bioswisstec) to obtain single-cell suspensions. Red blood cell lysis was  
 605 performed on splenocytes. SMG were minced and treated with 2 kU/ml collagenase II (Gibco) and  
 606 1 kU/ml DNase I (Roche) in CMR RPMI1640/10% FCS/0.1 mM non-essential amino acids/10 mM  
 607 HEPES/100 U/ml penicillin/0.1 mg/ml streptomycin/2 mM L-glutamine/1 mM sodium pyruvate) for  
 608 30 min at 37°C, passed through a 70- $\mu$ m cell strainer, and washed with PBS/5 mM EDTA. Cell  
 609 suspensions were stained with Zombie Fixable Viability Kit (BioLegend) for 15 min on ice. Fc  
 610 receptors were blocked with an anti-mouse CD16/32 antibody (BioLegend) for 10 min on ice. Cell  
 611 surface staining was performed in FACS buffer (PBS/2% FCS/1 mM EDTA) for 20 min on ice using  
 612 the following antibodies:

Antibody	Clone	Company	Order number
Anti-CD8 $\alpha$ -APC/Fire750	53-6.7	BioLegend	100766
Anti-CD44-BV605	IM7	BioLegend	103047
Anti-CD45-BV711	30-F11	BioLegend	103147
Anti-CD62L-BV421	MEL-14	BioLegend	104436
Anti-CD103-APC	2E7	BioLegend	121414

613

614 Cell suspensions were washed with FACS buffer (PBS/2% FCS/1 mM EDTA) and fixed and  
615 permeabilized using the BD Cytotfix/Cytoperm kit following the manufacturer's instructions.

616 Intracellular staining was performed for 40 min on ice using the following antibodies or Phalloidin-  
617 TRITC (Sigma-Aldrich) in Perm-Wash solution:

Antibody	Clone	Company	Order number
Anti-ERM	polyclonal	Cell Signaling	3142
Anti-pCofilin	polyclonal	Cell Signaling	3313
Anti-pERM	polyclonal	Cell Signaling	3141
Anti-pMLC	polyclonal	Cell Signaling	3674

618

619 Cell suspensions were washed with Perm/Wash and stained with Biotin-SP AffiniPure Goat Anti-  
620 Rabbit IgG (Jackson Immuno Research, 111-065-144) for 40 min on ice before washing again and  
621 staining with streptavidin-PE (BioLegend) for 20 min on ice. Cells were washed again and acquired  
622 on Attune NxT Flow Cytometer (ThermoFisher) or LSR Fortessa (BD). Data were analyzed with  
623 FlowJo.

624

#### 625 *Immunofluorescence*

626 OT-I memory cells were isolated from SMG and spleen at > 30 d p.i. LCMV-OVA-infected C57BL/6  
627 mice. Single cell suspensions of SMG and spleen were generated as above and sorted for tdT<sup>+</sup> T  
628 cells. Ibidi sticky slides (untreated side) with a 12-well removable chamber were coated with 10  
629 µg/ml fibronectin (Sigma-Aldrich). Cells were added and incubated 2 h at 37°C, fixed with 4%  
630 paraformaldehyde for 20 min at RT, washed and permeabilized using BD Fixation/Permeabilization  
631 solution 20 min at 4°C. Cells were blocked with BD Perm/Wash 2% goat serum for 1 h at RT,  
632 stained with rabbit anti-pMLC (Cell signaling, 3674) o.n. at 4°C, washed, stained with a goat anti-  
633 rabbit AF647 (Invitrogen, A32733) for 1 h at RT and washed again. The 12-well removable  
634 chamber was removed and the sticky slide was mounted on a glass slide with Prolong Gold  
635 Antifade with DAPI (ThermoFisher) and let dry at RT for 24 h. Images were taken with a Leica SP5  
636 confocal microscope using a 63x glycerin objective (APO CS, NA 1.3). Data were analyzed with  
637 Imaris (Bitplane). For SMG sections, SMG were frozen in OCT and cryosectioned for

638 immunofluorescence (6 or 10  $\mu$ m), followed by labeling with goat anti-GFP (Rockland, 600-101-  
639 215) and anti-EpCAM AF647 (BioLegend, 118212) for epithelium,

640

#### 641 *2PM image acquisition and analysis*

642 2PM intravital imaging of SMG was performed as described (97). In brief, mice were anesthetized  
643 with ketamine/xylazine/acepromazine and the right SMG lobe was surgically exposed. Baseline  
644 image sequences were acquired before 200  $\mu$ g/mouse Y27632 or 300  $\mu$ g/mouse AACOCF3 were  
645 injected i.p. Alternatively, BAPTA-AM (20 or 50  $\mu$ M) was overlaid in saline for 20 min. Twenty min  
646 to 3 h after Y27632 or 1 to 4 h after AACOCF3 or BAPTA-AM administration, further image  
647 sequences were recorded of the same surgical preparation. 2PM imaging was carried out with a  
648 TrimScope 2PM system (LaVision Biotec) using a 25X Nikon (NA 1.0) objective and a Ti:sapphire  
649 laser (Mai Tai HP, Spectraphysics) tuned to 780 or 840 nm. ImSpector software was used to  
650 control the 2PM system and acquire images with an automated system providing real-time drift  
651 correction (98). Eleven to sixteen x-y slices with a z-step size of 4  $\mu$ m were acquired in 0-100  $\mu$ m  
652 depth with a time interval of 20 s for 20-30 min. Emitted light and second harmonic signals were  
653 detected through 447/55-nm, 525/50-nm, 593/40-nm and 655/40-nm bandpass filters with non-  
654 descanned detectors. Data were analyzed with Imaris (Bitplane) and a customized script for arrest  
655 coefficient analysis with a threshold of 4  $\mu$ m/min as described (26).

656

#### 657 *Under agarose and confinement chamber assays*

658  $T_N$  were isolated from spleen and PLN of a naive mouse using the EasySep<sup>TM</sup> Mouse CD8<sup>+</sup> T cell  
659 Isolation Kit (Stem Cell Technologies) or the MojoSort Mouse CD8<sup>+</sup> T cell Isolation Kit (BioLegend)  
660 according to manufacturer's instructions.  $T_{RM}$  were isolated from SMG, LG or SI of > 30 d LCMV-  
661 OVA-infected C57BL/6 mice by flow cytometry sorting. A 17-mm diameter circle was cut into the  
662 center of 60-mm dishes. The hole was sealed from the bottom part of the dish using aquarium  
663 silicone (Marina) and a 24-mm glass coverslip or an Ibidi sticky slide. After the silicone dried, we  
664 overlaid a 5 mm-high ring cut from a 15-ml falcon tube and sealed the borders with aquarium  
665 silicone. For  $T_{RM}$  migration coverslips were washed with PBS and coated with 2% fatty acid-free  
666 human serum albumin (HSA; A-1887, Sigma) for 1 h at 37°C. For a "slippery" surface, Ibidi sticky

667 slides (untreated side) were coated with 1% Pluronic F-127 (Invitrogen, P6866) for 1 h at RT. For  
668  $T_N$  migration coverslips were coated with 20  $\mu$ g/ml Protein A (6500-10, BioVision) for 1 h at 37°C,  
669 washed 3 times with PBS and blocked with 1.5 % BSA for 1 h at 37°C. After washing once with  
670 PBS, cover glasses were coated for 2 h at 37°C with 100 nM recombinant ICAM1-Fc (796IC, R&D  
671 Systems) and washed 2 times with PBS. The coverslips were blocked again with 1.5 % BSA for 1  
672 h at 37°C and washed once with PBS. Five ml of 2 x HBSS and 10 ml of 2 x CMR containing 1%  
673 HSA (for  $T_{RM}$ ) and 20% FBS (for  $T_N$ ) were mixed and heated in a water bath to 56°C. One hundred  
674 mg SeaKem Gold Agarose (50152, Lonza) was dissolved and heated in 5 ml MilliQ water before  
675 adding to the prewarmed medium to give a final 0.5% agarose concentration. After cooling down to  
676 37°C, 500  $\mu$ l of the agarose mix was added on top of the coverslip. For  $T_N$  experiments, 100 nM  
677 CCL19 (Peprotech, 250-27B) were added to the agar. The agar was let to solidify first 5 min at RT  
678 and then 20 min at 4°C. We punched a sink hole (diameter approximately 2 mm) in the agarose on  
679 the side. For experiments with inhibitors, cells were incubated with the inhibitor for 1 h at 37°C  
680 before the experiment and the inhibitor was also present in the agarose. Sorted or isolated T cell  
681 populations were pelleted in an Eppendorf tube. In some experiments,  $2 \times 10^4$  SMG  $T_{RM}$  were  
682 mixed with  $0.2 \times 10^6$  1 nM OVA<sub>257-264</sub>-pulsed B cells isolated using the EasySep™ Mouse B cell  
683 Isolation Kit (Stem Cell Technologies) and labelled with 2.5  $\mu$ M CMTMR together with  $1 \times 10^6$   
684 unpulsed, non-labelled B cells in the presence of 100 ng/ml BAFF (R&D systems, 8876-BF-010).  
685 Cells were resuspended in the smallest possible achievable volume (ca. 2-5  $\mu$ l) and 1  $\mu$ l were  
686 injected in the opposite side from the sink hole using a 2.5- $\mu$ l Eppendorf pipette. From the sink  
687 hole, surplus of medium was collected to confine cells between the agarose and the glass slide.  
688 Time-lapse images were taken from the center of the dish using a Zeiss fluorescent microscope  
689 (AxioObserver, Zeiss) or a GE DeltaVision Elite widefield fluorescent microscope (U plan, S Apo,  
690 NA 0.75). Images were taken every 20 s for 15-20 min. For the TIRF images the GE DeltaVision  
691 microscope was used with a laser module and a 60X TIRF objective.  
692 A Dynamic Cell Confiner device (4Dcell, France) was used to study  $T_{RM}$  cell migration under  
693 defined chamber heights. Polydimethylsiloxane suction cups with 4  $\mu$ m or 7  $\mu$ m-high micropillars  
694 were prepared as described in the manufacturer's instructions. Plates were coated with 2% HSA.  
695 Sorted SMG  $T_{RM}$  ( $10^5$  cells) were transferred into each plate. Before imaging, the suction cup was

696 plugged to an adjustable vacuum source. Once confined at a pressure from -50 to -100 mbar, cells  
697 were imaged with a GE DeltaVision microscope as above.

698

#### 699 *Dynamic and morphometric cell analysis*

700 Cortical F-actin flow in TIRF image sequences was measured using the Imaris (Bitplane) particle  
701 tracking function to generate tracks of GFP<sup>+</sup> F-actin speckles, as previously described (35, 36, 99).  
702 The global speed depicts displacement over tracking time for each track. Morphometric data were  
703 analyzed with Imaris or a custom-made FIJI plugin (source code is available at  
704 [https://github.com/MatthieuPalayret/DynMorpho\\_Analysis](https://github.com/MatthieuPalayret/DynMorpho_Analysis)). For dynamic and morphometric cell  
705 analysis, cell contours were determined using the ADAPT plugin (100). Cells which areas were  
706 exceedingly high or low ( $<505 \text{ pixel}^2$  and  $>10,000 \text{ pixel}^2$ ) were excluded. Intersecting cell contours  
707 in consecutive frames were linked to form cell trajectories. When a trajectory evidenced a dramatic  
708 increase or decrease of the area of its cell in consecutive frames (with a ratio of areas  $> 150\%$ ),  
709 this was interpreted as the encounter or the separation of two distinct trajectories, and the original  
710 trajectory was consequently split in two (one trajectory ending before this event, and the other one  
711 beginning after it). Trajectories shorter than 6 frames were discarded. All trajectories were further  
712 visually qualitatively confronted to the original acquisition, and incorrect trajectories were manually  
713 split or rejected. For each cell contour in each frame, protrusions were defined as regions of the  
714 cells where the curvature (averaged over a specified window of 6 pixels of radius) of its contour  
715 was negative, denoting a zone with concave extrema (**Fig. S2**). When the area of a protrusion was  
716 smaller than a specified value ( $30 \text{ pixel}^2$ ) or larger than a specified proportion of the area of the cell  
717 ( $> 30\%$ ), the protrusion was excluded from further analysis. Finally, to exclude the uropod from the  
718 protrusion analysis, a uropod was defined as the furthest protrusion from the leading edge of the  
719 cell (as defined by the direction taken by the cell from its positions in the previous two frames).  
720 For each trajectory, the dynamic and morphometric analysis consisted in calculating six outputs:  
721 the average speed of the cell; the meandering index of the trajectory, which is a measure of its  
722 linearity, calculated as the ratio of the distance separating the initial and final points of the  
723 trajectory over the distance travelled by the cell (the ratio equals 1 if the trajectory is exactly linear);  
724 the average area of the cell; its average circularity coefficient, calculated as the average over the

725 trajectory, of the ratio of the true area of the cell over the area of a circular cell which would have  
726 the same perimeter ( $= 4\pi \times \text{area}/\text{perimeter}^2$  - the coefficient equals 100 when the cell is perfectly  
727 circular); and both the average number and size of the protrusions of the cell (the uropod being  
728 excluded) over its whole trajectory.

729

### 730 *3D collagen matrix migration*

731  $T_{RM}$  migration through a confined three-dimensional collagen type I matrix was performed in  $\mu$ -  
732 Slide Chemotaxis ibiTreat chambers (ibidi, Switzerland) as described (101). Briefly, sorted LifeAct-  
733 GFP x mT/mG  $T_{RM}$  were resuspended at  $5 \times 10^5$  cells/ml in RPMI 1640 medium supplemented with  
734 10% heat inactivated FCS. 30  $\mu$ l PureCol collagen I (CellSystems, Troisdorf, Germany), 4  $\mu$ l 10x  
735 DMEM, and 2  $\mu$ l 7.5%  $\text{NaHCO}_3$  were premixed, carefully mixed with 18  $\mu$ l cell suspension, and  
736 applied to  $\mu$ -slide chemotaxis chambers. Collagen was allowed to polymerize for 40 min at 37°C in  
737 a humidified incubator. Live cell imaging was performed on a laser scanning microscope (Leica  
738 TCS SP5; Leica, Switzerland) using an HCX PL APO CS 63.0x (NA1.40) OIL UV objective at 0.65  
739 sec intervals on a microscope stage fitted with a Tokai Hit Thermoplate at 37°C.

740

### 741 *MCMV rechallenge and cluster analysis*

742 MCMV rechallenge experiments were performed as described (26). In brief, GFP<sup>+</sup> OT-I cells ( $5 \times$   
743  $10^4$ /mouse) were transferred into C57BL/6 mice and i.p. infected on the following day with  $10^5$  pfu  
744 LCMV-OVA. At > 30 d p.i., mice were treated with vehicle (DMSO) or 300  $\mu$ g AACOCF<sub>3</sub>, together  
745 with anti- $\alpha 4$  (clone PS/2) and anti- $\alpha_L$  (LFA-1) (clone FD441.8; each 100  $\mu$ g/mouse) mAbs (26).  
746 After 2 h,  $10^6$  pfu of the attenuated MCMV-3D- $\Delta$ vRAP strain expressing the SIINFEKL peptide  
747 epitope (102) were locally administered to the right SMG via Wharton's duct injection. Recipient  
748 mice were treated every 12 h with 300  $\mu$ g AACOCF<sub>3</sub> or vehicle (final volume 100  $\mu$ l in saline) and  
749 at 48 h p.i. again with PS/2 and FD441.8 as above. Alternatively, we administered daily 2  $\mu$ g/g  
750 body weight FTY720. On day 3 (68 h after MCMV injection), mice were perfused with 4% PFA and  
751 the right SMG was harvested, fixed o.n. at 4°C in 5 mL 4% PFA/PBS, transferred into 30% sucrose  
752 and kept at 4°C for 24 h. SMG were frozen in OCT and cryosectioned for immunofluorescence (6  
753 or 10  $\mu$ m), followed by labeling with goat anti-GFP (Rockland, 600-101-215) and donkey anti-goat



754 AF488 (ThermoFisher, A11055), and rabbit anti-RFP (Abcam, ab62341) and donkey anti-rabbit  
755 AF555 (ThermoFisher, A32794), for viral foci. Tile scans were obtained by widefield (DeltaVision)  
756 or confocal (Leica Stellaris Falcon 8) fluorescence microscopy and T<sub>RM</sub> were identified using the  
757 Imaris “spots” function. 9 neighbor-clusters were empirically defined by choosing a maximum  
758 distance of 62  $\mu$ m between spots. The percentage of clustered cells was obtained by dividing the  
759 number of clustered over total number of spots.

760

#### 761 *Statistical analysis*

762 Two-tailed, unpaired Student’s t-test, Mann-Whitney U-test, one-way ANOVA with Dunn’s multiple  
763 comparisons test, Kruskal-Wallis test, or a Wilcoxon rang test was used to determine statistical  
764 significance (Prism, GraphPad). Whiskers in “box and whisker” plots depict a range of 90-100% of  
765 individual values (non-included values are shown as individual dots), while the box comprises 50%  
766 of all data points and the line within the box displaying the median. Significance was set at  $p <$   
767 0.05.

768

#### 769 **Supplementary materials**

770 Figure S1. Flow cytometry of memory T cells.

771 Figure S2. Outline of morphometric analysis.

772 Figure S3. Autonomous SMG T<sub>RM</sub> motility requires constitutive DOCK2-Rac-Arp2/3 signaling.

773 Figure S4. Genetic depletion of MYH9 impairs T cell development and *in vivo* expansion.

774 Figure S5. SMG T<sub>RM</sub> motility requires Rho signaling.

775 Figure S6. T cell motility under confinement.

776 Figure S7. Gene expression analysis.

777 Figure S8. Characterization of SMG viral rechallenge experiment and inhibitors.

778 Movie 1. Intravital imaging of OT-I T<sub>RM</sub> migration in SMG during the memory phase following  
779 LCMV-OVA infection.

780 Movie 2. TIRF time-lapse video of F-actin dynamics in LifeAct-GFP<sup>+</sup> OT-I T<sub>N</sub> in under agarose  
781 assay.

782 Movie 3. TIRF time-lapse video of F-actin dynamics in LifeAct-GFP<sup>+</sup> SMG OT-I T<sub>RM</sub> in under  
783 agarose assay.

784 Movie 4. Widefield fluorescent microscopy time-lapse video of OT-I T<sub>N</sub> in under agarose assay on  
785 HSA or CCL19 and ICAM-1.

786 Movie 5. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under agarose  
787 assay on HSA or CXCL10, CXCL10 and ICAM-1.

788 Movie 6. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under agarose  
789 assay on HSA and CPYPP or CK666.

790 Movie 7. Intravital imaging of DOCK2<sup>-/-</sup> and WT OT-I T<sub>RM</sub> in SMG during the memory phase  
791 following LCMV-OVA infection.

792 Movie 8. Widefield fluorescent microscopy time-lapse video of DsRed<sup>+</sup> MYH-GFP<sup>+</sup> SMG OT-I T<sub>RM</sub>  
793 in under agarose assay on HSA.

794 Movie 9. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under agarose  
795 assay on HSA and MLCK or Y-27632.

796 Movie 10. Widefield fluorescent microscopy time-lapse video of mT/mG<sup>+</sup> LifeAct-GFP<sup>+</sup> or DOCK2-  
797 GFP<sup>+</sup> SMG OT-I T<sub>RM</sub> in under agarose assay, followed by confocal microscopy time-lapse image  
798 sequence of mT/mG<sup>+</sup> LifeAct-GFP<sup>+</sup> SMG OT-I T<sub>RM</sub> in 3D collagen matrix.

799 Movie 11. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in confinement  
800 chamber with micropillars of 7 μm or 4 μm height.

801 Movie 12. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under agarose  
802 assay on HSA with EtOH, AACOCF<sub>3</sub> and AACOCF<sub>3</sub> + AA.

803 Movie 13. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under agarose  
804 assay on HSA with DMSO, BAPTA-AM and 2APB.

805 Movie 14. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under agarose  
806 assay on HSA with OVA<sub>257-264</sub>-pulsed and unpulsed B cells with or without AACOCF<sub>3</sub>.

807 Movie 15. Intravital imaging of SMG T<sub>RM</sub> before and after BAPTA-AM (50 μM) superfusion.  
808

## 809 **References**

- 810 1. J. W. Griffith, C. L. Sokol, A. D. Luster, Chemokines and Chemokine Receptors: Positioning Cells  
811 for Host Defense and Immunity. *Immunology* 32, 659–702 (2014).
- 812 2. J. V. Stein, N. Ruef, Regulation of global CD8+ T-cell positioning by the actomyosin  
813 cytoskeleton. *Immunol Rev* 289, 232–249 (2019).
- 814 3. D. Masopust, J. M. Schenkel, The integration of T cell migration, differentiation and function. *Nat*  
815 *Rev Immunol* 13, 309–320 (2013).
- 816 4. J. R. Groom, Regulators of T-cell fate: Integration of cell migration, differentiation and function.  
817 *Immunol Rev* 289, 101–114 (2019).
- 818 5. D. J. Fowell, M. Kim, The spatio-temporal control of effector T cell migration. *Nat Rev Immunol*  
819 21, 582–596 (2021).
- 820 6. N. Iijima, A. Iwasaki, Tissue instruction for migration and retention of TRM cells. *Trends Immunol*  
821 36, 556–564 (2015).
- 822 7. S. N. Mueller, L. K. Mackay, Tissue-resident memory T cells: local specialists in immune  
823 defence. *Nat. Rev. Immunol.* 16, 79–89 (2016).
- 824 8. A. Zaid, J. L. Hor, S. N. Christo, J. R. Groom, W. R. Heath, L. K. Mackay, S. N. Mueller,  
825 Chemokine Receptor–Dependent Control of Skin Tissue–Resident Memory T Cell Formation. *J.*  
826 *Immunol.* 199, 2451–2459 (2017).
- 827 9. P. C. Rosato, L. K. Beura, D. Masopust, Tissue resident memory T cells and viral immunity. *Curr*  
828 *Opin Virol* 22, 44–50 (2017).
- 829 10. P. A. Szabo, M. Miron, D. L. Farber, Location, location, location: Tissue resident memory T  
830 cells in mice and humans. *Sci Immunol* 4, eaas9673 (2019).
- 831 11. S. C. Sasson, C. L. Gordon, S. N. Christo, P. Klenerman, L. K. Mackay, Local heroes or  
832 villains: tissue-resident memory T cells in human health and disease. *Cell. Mol. Immunol.* 17, 113–  
833 122 (2020).
- 834 12. S. K. Bromley, H. Akbaba, V. Mani, R. Mora-Buch, A. Y. Chasse, A. Sama, A. D. Luster,  
835 CD49a Regulates Cutaneous Resident Memory CD8+ T Cell Persistence and Response. *Cell*  
836 *Reports* 32, 108085 (2020).
- 837 13. M. Heeg, A. W. Goldrath, Insights into phenotypic and functional CD8+ TRM heterogeneity.  
838 *Immunol. Rev.* (2023), doi:10.1111/imr.13218.
- 839 14. P. Friedl, B. Weigelin, Interstitial leukocyte migration and immune function. *Nat Immunol* 9,  
840 960–969 (2008).
- 841 15. T. Lämmermann, M. Sixt, Mechanical modes of ‘amoeboid’ cell migration. *Curr Opin Cell Biol*  
842 21, 636–644 (2009).
- 843 16. D. L. Bodor, W. Pönisch, R. G. Endres, E. K. Paluch, Of Cell Shapes and Motion: The Physical  
844 Basis of Animal Cell Migration. *Dev Cell* 52, 550–562 (2020).
- 845 17. E. K. Paluch, I. M. Aspalter, M. Sixt, Focal Adhesion-Independent Cell Migration. *Annu Rev*  
846 *Cell Dev Biol* 32, 469–490 (2016).

- 847 18. L. K. Fritz-Laylin, The evolution of animal cell motility. *Curr Biol* 30, R477–R482 (2020).
- 848 19. S. SenGupta, C. A. Parent, J. E. Bear, The principles of directed cell migration. *Nat Rev Mol*  
849 *Cell Bio* 22, 529–547 (2021).
- 850 20. T. Okada, J. G. Cyster, CC Chemokine Receptor 7 Contributes to Gi-Dependent T Cell Motility  
851 in the Lymph Node. *J Immunol* 178, 2973–2978 (2007).
- 852 21. T. Worbs, T. R. Mempel, J. Bölker, U. H. von Andrian, R. Förster, CCR7 ligands stimulate the  
853 intranodal motility of T lymphocytes in vivo. *J. Exp. Med.* 204, 489–495 (2007).
- 854 22. M. Faroudi, M. Hons, A. Zachacz, C. Dumont, R. Lyck, J. V. Stein, V. L. J. Tybulewicz, Critical  
855 roles for Rac GTPases in T-cell migration to and within lymph nodes. *Blood* 116, 5536–5547  
856 (2010).
- 857 23. M. Hons, A. Kopf, R. Hauschild, A. Leithner, F. Gaertner, J. Abe, J. Renkawitz, J. V. Stein, M.  
858 Sixt, Chemokines and integrins independently tune actin flow and substrate friction during  
859 intranodal migration of T cells. *Nat. Immunol.* 19, 606–616 (2018).
- 860 24. E. Woolf, I. Grigorova, A. Sagiv, V. Grabovsky, S. W. Feigelson, Z. Shulman, T. Hartmann, M.  
861 Sixt, J. G. Cyster, R. Alon, Lymph node chemokines promote sustained T lymphocyte motility  
862 without triggering stable integrin adhesiveness in the absence of shear forces. *Nat Immunol* 8,  
863 1076–1085 (2007).
- 864 25. R. T. Boscacci, F. Pfeiffer, K. Gollmer, A. I. C. Sevilla, A. M. Martin, S. F. Soriano, D. Natale, S.  
865 Henrickson, U. H. von Andrian, Y. Fukui, M. Mellado, U. Deutsch, B. Engelhardt, J. V. Stein,  
866 Comprehensive analysis of lymph node stroma-expressed Ig superfamily members reveals  
867 redundant and nonredundant roles for ICAM-1, ICAM-2, and VCAM-1 in lymphocyte homing. *Blood*  
868 116, 915–925 (2010).
- 869 26. B. Stolp, F. Thelen, X. Ficht, L. M. Altenburger, N. Ruef, V. V. G. K. Inavalli, P. Germann, N.  
870 Page, F. Moalli, A. Raimondi, K. A. Keyser, S. M. S. Jafari, F. Barone, M. S. Dettmer, D. Merkler,  
871 M. Iannacone, J. Sharpe, C. Schlapbach, O. T. Fackler, U. V. Nägerl, J. V. Stein, Salivary gland  
872 macrophages and tissue-resident CD8<sup>+</sup> T cells cooperate for homeostatic organ surveillance. *Sci*  
873 *Immunol* 5, eaaz4371 (2020).
- 874 27. C. E. Hughes, R. J. B. Nibbs, A guide to chemokines and their receptors. *FEBS J* 285, 2944–  
875 2971 (2018).
- 876 28. A. Reversat, F. Gaertner, J. Merrin, J. Stopp, S. Tasciyan, J. Aguilera, I. de Vries, R.  
877 Hauschild, M. Hons, M. Piel, A. Callan-Jones, R. Voituriez, M. Sixt, Cellular locomotion using  
878 environmental topography. *Nature* 582, 582–585 (2020).
- 879 29. A. J. Lomakin, C. J. Cattin, D. Cuvelier, Z. Alraies, M. Molina, G. P. F. Nader, N. Srivastava, P.  
880 J. Sáez, J. M. Garcia-Arcos, I. Y. Zhitnyak, A. Bhargava, M. K. Driscoll, E. S. Welf, R. Fiolka, R. J.  
881 Petrie, N. S. D. Silva, J. M. González-Granado, N. Manel, A. M. Lennon-Duménil, D. J. Müller, M.  
882 Piel, The nucleus acts as a ruler tailoring cell responses to spatial constraints. *Science* 370,  
883 eaba2894 (2020).
- 884 30. V. Venturini, F. Pezzano, F. C. Castro, H.-M. Häkkinen, S. Jiménez-Delgado, M. Colomer-  
885 Rosell, M. Marro, Q. Tolosa-Ramon, S. Paz-López, M. A. Valverde, J. Weghuber, P. Loza-Alvarez,  
886 M. Krieg, S. Wieser, V. Ruprecht, The nucleus measures shape changes for cellular proprioception  
887 to control dynamic cell behavior. *Science* 370, eaba2644 (2020).
- 888 31. K. A. Hogquist, S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, F. R. Carbone, T cell  
889 receptor antagonist peptides induce positive selection. *Cell* 76, 17–27 (1994).

890 32. S. M. Kallert, S. Darbre, W. V. Bonilla, M. Kreutzfeldt, N. Page, P. Müller, M. Kreuzaler, M. Lu,  
891 S. Favre, F. Kreppel, M. Löhning, S. A. Luther, A. Zippelius, D. Merkler, D. D. Pinschewer,  
892 Replicating viral vector platform exploits alarmin signals for potent CD8<sup>+</sup> T cell-mediated tumour  
893 immunotherapy. *Nat Commun* 8, 15327 (2017).

894 33. J. Riedl, A. H. Crevenna, K. Kessenbrock, J. H. Yu, D. Neukirchen, M. Bista, F. Bradke, D.  
895 Jenne, T. A. Holak, Z. Werb, M. Sixt, R. Wedlich-Söldner, Lifeact: a versatile marker to visualize F-  
896 actin. *Nat Meth* 5, 605–607 (2008).

897 34. A. Babich, S. Li, R. S. O'Connor, M. C. Milone, B. D. Freedman, J. K. Burkhardt, F-actin  
898 polymerization and retrograde flow drive sustained PLC $\gamma$ 1 signaling during T cell activation. *J Cell*  
899 *Biol* 197, 775–787 (2012).

900 35. A. T. Ritter, Y. Asano, J. C. Stinchcombe, N. M. G. Dieckmann, B.-C. Chen, C. Gawden-Bone,  
901 S. van Engelenburg, W. Legant, L. Gao, M. W. Davidson, E. Betzig, J. Lippincott-Schwartz, G. M.  
902 Griffiths, Actin Depletion Initiates Events Leading to Granule Secretion at the Immunological  
903 Synapse. *Immunity* 42, 864–876 (2015).

904 36. W. A. Comrie, A. Babich, J. K. Burkhardt, F-actin flow drives affinity maturation and spatial  
905 organization of LFA-1 at the immunological synapse. *J Cell Biol* 208, 475–491 (2015).

906 37. M. Bajénoff, J. G. Egen, L. Y. Koo, J. P. Laugier, F. Brau, N. Glaichenhaus, R. N. Germain,  
907 Stromal Cell Networks Regulate Lymphocyte Entry, Migration, and Territoriality in Lymph Nodes.  
908 *Immunity* 25, 989–1001 (2006).

909 38. J. Renkawitz, K. Schumann, M. Weber, T. Lämmermann, H. Pflücke, M. Piel, J. Polleux, J. P.  
910 Spatz, M. Sixt, Adaptive force transmission in amoeboid cell migration. *Nat Cell Biol* 11, 1438–  
911 1443 (2009).

912 39. D. Bray, J. G. White, Cortical Flow in Animal Cells. *Science* 239, 883–888 (1988).

913 40. Y. Fukui, O. Hashimoto, T. Sanui, T. Oono, H. Koga, M. Abe, A. Inayoshi, M. Noda, M. Oike, T.  
914 Shirai, T. Sasazuki, Haematopoietic cell-specific CDM family protein DOCK2 is essential for  
915 lymphocyte migration. *Nature* 412, 826–831 (2001).

916 41. A. Leithner, A. Eichner, J. Müller, A. Reversat, M. Brown, J. Schwarz, J. Merrin, D. J. J. de  
917 Gorter, F. Schur, J. Bayerl, I. de Vries, S. Wieser, R. Hauschild, F. P. L. Lai, M. Moser, D.  
918 Kerjaschki, K. Rottner, J. V. Small, T. E. B. Stradal, M. Sixt, Diversified actin protrusions promote  
919 environmental exploration but are dispensable for locomotion of leukocytes. *Nat Cell Biol* 18,  
920 1253–1259 (2016).

921 42. P. Vargas, P. Maiuri, M. Bretou, P. J. Sáez, P. Pierobon, M. Maurin, M. Chabaud, D. Lankar,  
922 D. Obino, E. Terriac, M. Raab, H.-R. Thiam, T. Brouck, S. M. Kitchen-Goosen, A. S. Alberts, P.  
923 Sunareni, S. Xia, R. Li, R. Voituriez, M. Piel, A.-M. Lennon-Duménil, Innate control of actin  
924 nucleation determines two distinct migration behaviours in dendritic cells. *Nat Cell Biol* 18, 43–53  
925 (2016).

926 43. L. K. Fritz-Laylin, S. J. Lord, R. D. Mullins, WASP and SCAR are evolutionarily conserved in  
927 actin-filled pseudopod-based motility. *J Cell Biol* 216, 1673–1688 (2017).

928 44. A. Nishikimi, T. Uruno, X. Duan, Q. Cao, Y. Okamura, T. Saitoh, N. Saito, S. Sakaoka, Y. Du,  
929 A. Suenaga, M. Kukimoto-Niino, K. Miyano, K. Gotoh, T. Okabe, F. Sanematsu, Y. Tanaka, H.  
930 Sumimoto, T. Honma, S. Yokoyama, T. Nagano, D. Kohda, M. Kanai, Y. Fukui, Blockade of  
931 Inflammatory Responses by a Small-Molecule Inhibitor of the Rac Activator DOCK2. *Chem Biol* 19,  
932 488–497 (2012).

933 45. B. J. Nolen, N. Tomasevic, A. Russell, D. W. Pierce, Z. Jia, C. D. McCormick, J. Hartman, R.  
934 Sakowicz, T. D. Pollard, Characterization of two classes of small molecule inhibitors of Arp2/3  
935 complex. *Nature* 460, 1031–1034 (2009).

936 46. H. Jiang, F. Pan, L. M. Erickson, M.-S. Jang, T. Sanui, Y. Kunisaki, T. Sasazuki, M. Kobayashi,  
937 Y. Fukui, Deletion of DOCK2, a regulator of the actin cytoskeleton in lymphocytes, suppresses  
938 cardiac allograft rejection. *J Exp Medicine* 202, 1121–1130 (2005).

939 47. Q. Zhang, C. G. Dove, J. L. Hor, H. M. Murdock, D. M. Strauss-Albee, J. A. Garcia, J. N.  
940 Mandl, R. A. Grodick, H. Jing, D. B. Chandler-Brown, T. E. Lenardo, G. Crawford, H. F. Matthews,  
941 A. F. Freeman, R. J. Cornall, R. N. Germain, S. N. Mueller, H. C. Su, DOCK8 regulates  
942 lymphocyte shape integrity for skin antiviral immunity. *J. Exp. Med.* 211, 2549–2566 (2014).

943 48. K. M. Yamada, M. Sixt, Mechanisms of 3D cell migration. *Nat Rev Mol Cell Bio* 20, 738–752  
944 (2019).

945 49. Y. Zhang, M. A. Conti, D. Malide, F. Dong, A. Wang, Y. A. Shmist, C. Liu, P. Zerfas, M. P.  
946 Daniels, C.-C. Chan, E. Kozin, B. Kachar, M. J. Kelley, J. B. Kopp, R. S. Adelstein, Mouse models  
947 of MYH9-related disease: mutations in nonmuscle myosin II-A. *Blood* 119, 238–250 (2012).

948 50. A. Zehrer, R. Pick, M. Salvermoser, A. Boda, M. Miller, K. Stark, L. T. Weckbach, B. Walzog,  
949 D. Begandt, A Fundamental Role of Myh9 for Neutrophil Migration in Innate Immunity. *The Journal*  
950 *of Immunology* 201, 1748–1764 (2018).

951 51. M. Vicente-Manzanares, X. Ma, R. S. Adelstein, A. R. Horwitz, Non-muscle myosin II takes  
952 centre stage in cell adhesion and migration. *Nat Rev Mol Cell Bio* 10, 778–790 (2009).

953 52. T. Isogai, R. van der Kammen, M. Innocenti, SMIFH2 has effects on Formins and p53 that  
954 perturb the cell cytoskeleton. *Sci Rep* 5, 9802–15 (2015).

955 53. Y. Nishimura, S. Shi, F. Zhang, R. Liu, Y. Takagi, A. D. Bershadsky, V. Viasnoff, J. R. Sellers,  
956 The Formin Inhibitor, SMIFH2, Inhibits Members of the Myosin Superfamily. *J Cell Sci* 134,  
957 jcs.253708 (2021).

958 54. T. F. Robertson, P. Chengappa, D. G. Atria, C. F. Wu, L. Avery, N. H. Roy, I. Maillard, R. J.  
959 Petrie, J. K. Burkhardt, Lymphocyte egress signal sphingosine-1-phosphate promotes ERM-  
960 guided, bleb-based migration. *J Cell Biol* 220, e202007182 (2021).

961 55. P. Kameritsch, J. Renkawitz, Principles of Leukocyte Migration Strategies. *Trends in Cell*  
962 *Biology* 30, 818–832 (2020).

963 56. A. Smith, P. Stanley, K. Jones, L. Svensson, A. McDowall, N. Hogg, The role of the integrin  
964 LFA-1 in T-lymphocyte migration. *Immunol Rev* 218, 135–146 (2009).

965 57. T. Wolf, W. Jin, G. Zoppi, I. A. Vogel, M. Akhmedov, C. K. E. Bleck, T. Beltraminelli, J. C.  
966 Rieckmann, N. J. Ramirez, M. Benevento, S. Notarbartolo, D. Bumann, F. Meissner, B.  
967 Grimbacher, M. Mann, A. Lanzavecchia, F. Sallusto, I. Kwee, R. Geiger, Dynamics in protein  
968 translation sustaining T cell preparedness. *Nat Immunol* 21, 927–937 (2020).

969 58. A. D. Weems, E. S. Welf, M. K. Driscoll, F. Y. Zhou, H. Mazloom-Farsibaf, B.-J. Chang, V. S.  
970 Murali, G. M. Gihana, B. G. Weiss, J. Chi, D. Rajendran, K. M. Dean, R. Fiolka, G. Danuser, Blebs  
971 promote cell survival by assembling oncogenic signalling hubs. *Nature* 615, 517–525 (2023).

972 59. A. Smith, Y. R. Carrasco, P. Stanley, N. Kieffer, F. D. Batista, N. Hogg, A talin-dependent LFA-  
973 1 focal zone is formed by rapidly migrating T lymphocytes. *J Cell Biology* 170, 141–151 (2005).

974 60. P. R. O'Neill, J. A. Castillo-Badillo, X. Meshik, V. Kalyanaraman, K. Melgarejo, N. Gautam,  
975 Membrane Flow Drives an Adhesion-Independent Amoeboid Cell Migration Mode. *Dev Cell* 46, 9-  
976 22.e4 (2018).

977 61. L. Aoun, A. Farutin, N. Garcia-Seyda, P. Nègre, M. S. Rizvi, S. Tlili, S. Song, X. Luo, M.  
978 Biarnes-Pelicot, R. Galland, J.-B. Sibarita, A. Michelot, C. HIVROZ, S. Rafai, M.-P. Valignat, C.  
979 Misbah, O. Theodoly, Amoeboid Swimming Is Propelled by Molecular Paddling in Lymphocytes.  
980 *Biophys J* 119, 1157–1177 (2020).

981 62. A. Saha, M. Nishikawa, M. Behrndt, C.-P. Heisenberg, F. Jülicher, S. W. Grill, Determining  
982 Physical Properties of the Cell Cortex. *Biophysical Journal* 110, 1421–1429 (2016).

983 63. B. Enyedi, M. Jelcic, P. Niethammer, The Cell Nucleus Serves as a Mechanotransducer of  
984 Tissue Damage-Induced Inflammation. *Cell* 165, 1160–1170 (2016).

985 64. A. Selezneva, A. J. Gibb, D. Willis, The Nuclear Envelope as a Regulator of Immune Cell  
986 Function. *Front. Immun.* , 1–10 (2022).

987 65. M. Tymianski, M. C. Wallace, I. Spigelman, M. Uno, P. L. Carlen, C. H. Tator, M. P. Charlton,  
988 Cell-permeant Ca<sup>2+</sup> chelators reduce early excitotoxic and ischemic neuronal injury in vitro and in  
989 vivo. *Neuron* 11, 221–235 (1993).

990 66. Z. Shen, P. Niethammer, A cellular sense of space and pressure. *Science* 370, 295–296  
991 (2020).

992 67. J. T. Long, J. Lammerding, Nuclear Deformation Lets Cells Gauge Their Physical Confinement.  
993 *Dev Cell* 56, 156–158 (2021).

994 68. R. D. Mullins, P. Bieling, D. A. Fletcher, From solution to surface to filament: actin flux into  
995 branched networks. *Biophys Rev* 10, 1537–1551 (2018).

996 69. L. K. Mackay, A. Rahimpour, J. Z. Ma, N. Collins, A. T. Stock, M.-L. Hafon, J. Vega-Ramos, P.  
997 Lauzurica, S. N. Mueller, T. Stefanovic, D. C. Tschärke, W. R. Heath, M. Inouye, F. R. Carbone, T.  
998 Gebhardt, The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin.  
999 *Nat. Immunol.* 14, 1294–1301 (2013).

1000 70. M. Huse, Mechanical forces in the immune system. *Nat Rev Immunol* 17, 679–690 (2017).

1001 71. S. V. Paeon, M. A. Govendir, D. Kempe, M. Biro, Mechanoimmunology: molecular-scale  
1002 forces govern immune cell functions. *Mol Biol Cell* 29, 1919–1926 (2018).

1003 72. M. Chabaud, N. Paillon, K. Gaus, C. HIVROZ, Mechanobiology of antigen-induced T cell arrest.  
1004 *Biol. Cell* (2020), doi:10.1111/boc.201900093.

1005 73. H. Du, J. M. Bartleson, S. Butenko, V. Alonso, W. F. Liu, D. A. Winer, M. J. Butte, Tuning  
1006 immunity through tissue mechanotransduction. *Nat Rev Immunol* 23, 174–188 (2023).

1007 74. R. Basu, B. M. Whitlock, J. Husson, A. L. Floc'h, W. Jin, A. Oyler-Yaniv, F. Dotiwala, G.  
1008 Giannone, C. HIVROZ, N. Biais, J. Lieberman, L. C. Kam, M. Huse, Cytotoxic T Cells Use  
1009 Mechanical Force to Potentiate Target Cell Killing. *Cell* 165, 100–110 (2016).

1010 75. M. Tello-Lafoz, K. Srpan, E. E. Sanchez, J. Hu, J. Remsik, Y. Romin, A. Calò, D. Hoen, U.  
1011 Bhanot, L. Morris, A. Boire, K. C. Hsu, J. Massagué, M. Huse, E. E. Er, Cytotoxic lymphocytes  
1012 target characteristic biophysical vulnerabilities in cancer. *Immunity* 54, 1037-1054.e7 (2021).

1013 76. A. G. Solis, P. Bielecki, H. R. Steach, L. Sharma, C. C. D. Harman, S. Yun, M. R. de Zoete, J.  
1014 N. Warnock, S. D. F. To, A. G. York, M. Mack, M. A. Schwartz, Charles. S. D. Cruz, N. W. Palm, R.  
1015 Jackson, R. A. Flavell, Mechanosensation of cyclical force by PIEZO1 is essential for innate  
1016 immunity. *Nature* 573, 69–74 (2019).

1017 77. D. Liu, L. Duan, L. B. Rodda, E. Lu, Y. Xu, J. An, L. Qiu, F. Liu, M. R. Looney, Z. Yang, C. D.  
1018 C. Allen, Z. Li, A. Marson, J. G. Cyster, CD97 promotes spleen dendritic cell homeostasis through  
1019 the mechanosensing of red blood cells. *Science* 375, eabi5965 (2022).

1020 78. H. D. Moreau, M. Piel, R. Voituriez, A.-M. Lennon-Duménil, Integrating Physical and Molecular  
1021 Insights on Immune Cell Migration. *Trends Immunol* 39, 632–643 (2018).

1022 79. S. van Helvert, C. Storm, P. Friedl, Mechanoreciprocity in cell migration. *Nat Cell Biol* 20, 8–20  
1023 (2018).

1024 80. F. Moalli, X. Ficht, P. Germann, M. Vladymyrov, B. Stolp, I. de Vries, R. Lyck, J. Balmer, A.  
1025 Fiocchi, M. Kreutzfeldt, D. Merkler, M. Iannacone, A. Ariga, M. H. Stoffel, J. Sharpe, M. Bähler, M.  
1026 Sixt, A. Diz-Muñoz, J. V. Stein, The Rho regulator Myosin IXb enables nonlymphoid tissue seeding  
1027 of protective CD8<sup>+</sup> T cells. *J. Exp. Medicine* 215, 1869–1890 (2018).

1028 81. T. Lämmermann, B. L. Bader, S. J. Monkley, T. Worbs, R. Wedlich-Söldner, K. Hirsch, M.  
1029 Keller, R. Förster, D. R. Critchley, R. Fässler, M. Sixt, Rapid leukocyte migration by integrin-  
1030 independent flowing and squeezing. *Nature* 453, 51–55 (2008).

1031 82. J. Renkawitz, A. Kopf, J. Stopp, I. de Vries, M. K. Driscoll, J. Merrin, R. Hauschild, E. S. Welf,  
1032 G. Danuser, R. Fiolka, M. Sixt, Nuclear positioning facilitates amoeboid migration along the path of  
1033 least resistance. *Nature* 568, 546–550 (2019).

1034 83. Y. Kalukula, A. D. Stephens, J. Lammerding, S. Gabriele, Mechanics and functional  
1035 consequences of nuclear deformations. *Nat Rev Mol Cell Bio* , 1–20 (2022).

1036 84. B. Enyedi, P. Niethammer, A Case for the Nuclear Membrane as a Mechanotransducer. *Cell*  
1037 *Mol Bioeng* 9, 247–251 (2016).

1038 85. J. B. Park, C. S. Lee, J.-H. Jang, J. Ghim, Y.-J. Kim, S. You, D. Hwang, P.-G. Suh, S. H. Ryu,  
1039 Phospholipase signalling networks in cancer. *Nat Rev Cancer* 12, 782–792 (2012).

1040 86. C. C. Leslie, Cytosolic phospholipase A<sub>2</sub>: physiological function and role in disease. *J Lipid Res*  
1041 56, 1386–1402 (2015).

1042 87. F. Fenninger, W. A. Jefferies, What's Bred in the Bone: Calcium Channels in Lymphocytes.  
1043 *The Journal of Immunology* 202, 1021–1030 (2019).

1044 88. Z. Alraies, C. A. Rivera, M.-G. Delgado, D. Sanséau, M. Maurin, R. Amadio, G. M. Piperno, G.  
1045 Dunsmore, A. Yatim, L. L. Mariano, P. J. Sáez, M. Gratia, O. Lamiable, A. Moreau, A. Willart, B.  
1046 Albaud, P. Legoix, H. Nakano, D. N. Cook, T. Lawrence, N. Manel, F. Benvenuti, F. Ginhoux, H. D.  
1047 Moreau, G. P. F. Nader, M. Piel, A.-M. Lennon-Duménil, An Arp2/3-cPLA2-NFκB axis acts as a  
1048 Cell Shape Sensor to drive Homeostatic Migration of Dendritic Cells. *Biorxiv* , 2022.08.09.503223  
1049 (2022).

1050 89. B. C. Schaefer, M. L. Schaefer, J. W. Kappler, P. Marrack, R. M. Kedl, Observation of Antigen-  
1051 Dependent CD8<sup>+</sup> T-Cell/ Dendritic Cell Interactions in Vivo. *Cell Immunol* 214, 110–122 (2001).

1052 90. A. C. Kirby, M. C. Coles, P. M. Kaye, Alveolar Macrophages Transport Pathogens to Lung  
1053 Draining Lymph Nodes. *J Immunol* 183, 1983–1989 (2009).



1054 91. W. N. de Vries, L. T. Binns, K. S. Fancher, J. Dean, R. Moore, R. Kemler, B. B. Knowles,  
1055 Expression of Cre recombinase in mouse oocytes: A means to study maternal effect genes .  
1056 *Genesis* 26, 110–112 (2000).

1057 92. L. Madisen, T. A. Zwingman, S. M. Sunkin, S. W. Oh, H. A. Zariwala, H. Gu, L. L. Ng, R. D.  
1058 Palmiter, M. J. Hawrylycz, A. R. Jones, E. S. Lein, H. Zeng, A robust and high-throughput Cre  
1059 reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* 13, 133–140  
1060 (2010).

1061 93. M. D. Muzumdar, B. Tasic, K. Miyamichi, L. Li, L. Luo, A global double-fluorescent Cre reporter  
1062 mouse. *Genesis* 45, 593–605 (2007).

1063 94. J. Jacobelli, R. S. Friedman, M. A. Conti, A.-M. Lennon-Dumenil, M. Piel, C. M. Sorensen, R.  
1064 S. Adelstein, M. F. Krummel, Confinement-optimized three-dimensional T cell amoeboid motility is  
1065 modulated via myosin IIA–regulated adhesions. *Nat Immunol* 11, 953–961 (2010).

1066 95. Y. Harada, Y. Tanaka, M. Terasawa, M. Pieczyk, K. Habiro, T. Katakai, K. Hanawa-Suetsugu,  
1067 M. Kukimoto-Niino, T. Nishizaki, M. Shirouzu, X. Duan, T. Uruno, A. Nishikimi, F. Sanematsu, S.  
1068 Yokoyama, J. V. Stein, T. Kinashi, Y. Fukui, DOCK8 is a Cdc42 activator critical for interstitial  
1069 dendritic cell migration during immune responses. *Blood* 119, 4451–4461 (2012).

1070 96. Y. Kunisaki, A. Nishikimi, Y. Tanaka, R. Takii, M. Noda, A. Inayoshi, K. Watanabe, F.  
1071 Sanematsu, T. Sasazuki, T. Sasaki, Y. Fukui, DOCK2 is a Rac activator that regulates motility and  
1072 polarity during neutrophil chemotaxis. *J Cell Biology* 174, 647–652 (2006).

1073 97. X. Ficht, F. Thelen, B. Stolp, J. V. Stein, Preparation of Murine Submandibular Salivary Gland  
1074 for Upright Intravital Microscopy. *J Vis Exp* 215, 1869–1890 (2018).

1075 98. M. Vladymyrov, J. Abe, F. Moalli, J. V. Stein, A. Ariga, Real-time tissue offset correction  
1076 system for intravital multiphoton microscopy. *Journal of Immunological Methods* 438, 35–41  
1077 (2016).

1078 99. J. Daniel, A. G. Godin, M. Palayret, B. Lounis, L. Cognet, M. Blanchard-Desce, Innovative  
1079 molecular-based fluorescent nanoparticles for multicolor single particle tracking in cells. *J. Phys. D:  
1080 Appl. Phys.* 49, 084002 (2016).

1081 100. D. J. Barry, C. H. Durkin, J. V. Abella, M. Way, Open source software for quantification of cell  
1082 migration, protrusions, and fluorescence intensities. *J Cell Biol* 209, 163–180 (2015).

1083 101. E. U. Allmen, G. P. B. Samson, V. Purvanov, T. Maeda, D. F. Legler, CAL-1 as Cellular Model  
1084 System to Study CCR7-Guided Human Dendritic Cell Migration. *Front Immunol* 12, 702453 (2021).

1085 102. S. Halle, K. A. Keyser, F. R. Stahl, A. Busche, A. Marquardt, X. Zheng, M. Galla, V.  
1086 Heissmeyer, K. Heller, J. Boelter, K. Wagner, Y. Bischoff, R. Martens, A. Braun, K. Werth, A.  
1087 Uvarovskii, H. Kempf, M. Meyer-Hermann, R. Arens, M. Kremer, G. Sutter, M. Messerle, R.  
1088 Förster, In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions  
1089 and T Cell Cooperativity. *Immunity* 44, 233–245 (2016).

1090  
1091

1092 **Acknowledgments**

1093 We thank M. Sixt for critical feedback on the manuscript.

1094

1095 **Funding**

1096 This work was funded by Swiss National Foundation (SNF) project grants 31003A\_172994,  
1097 310030L\_197711, 310030\_200406, Sinergia project grant CRSII5\_170969 (to JVS), Leopoldina  
1098 fellowship LPDS 2011-16 and the Deutsche Forschungsgemeinschaft project number 240245660-  
1099 SFB1129 (project 8) (to BS). This work benefitted from the BioImage Light Microscopy Facility and  
1100 Cell Analytics Facility of the University of Fribourg.

1101

1102 **Author contributions**

1103 NR and JMM performed most experiments and analysis with help from XF, VP, SW, PP, BS, FT  
1104 and JBdA. MP wrote the script for morphometric analysis and PG provided scripts for *in vivo* cell  
1105 tracking. JA, JS, DFL and JVS supervised the work. JVS wrote the manuscript with input by all  
1106 coauthors.

1107

1108 **Competing interests**

1109 The authors declare no competing interests.

1110

1111 **Data and materials availability**

1112 All data needed to evaluate the conclusions in the paper are present in the paper or the  
1113 Supplementary Materials.

1114

1115 **Figure legends**

1116 **Figure 1. SMG T<sub>RM</sub> autonomously generate F-actin flow for chemokine- and specific**  
1117 **adhesion-independent amoeboid motility. A.** Experimental layout. **B.** Flow cytometry plots and  
1118 quantification of F-actin content in LN and spleen (Spl) T<sub>N</sub>, T<sub>CM</sub>, T<sub>EM</sub> and SMG T<sub>RM</sub>. Bars represent  
1119 median. **C.** TIRF images of cortical F-actin flow in LifeAct-GFP<sup>+</sup> T<sub>N</sub> and SMG T<sub>RM</sub> under agarose.  
1120 Note that for T<sub>N</sub> plated in the absence of chemokine (- CK), there is no front or rear discernible,  
1121 since these cells are non-polarized. Yellow lines indicate rearward (continuous) and forward  
1122 (dotted) F-actin flow. CK, chemokine; HSA, human serum albumin. **D.** Global F-actin flow speeds  
1123 in T<sub>N</sub> and SMG T<sub>RM</sub>. **E.** Schematic layout of dynamic and morphometric analysis. Scale bar, 10  $\mu$ m.  
1124 **F.** Wide-field fluorescence microscopy images of T<sub>N</sub> and SMG T<sub>RM</sub> under agarose migration. Time  
1125 in min:s; Scale bar, 10  $\mu$ m. **G.** Dynamic and morphometric analysis of T<sub>N</sub> and SMG T<sub>RM</sub>  
1126 displacement. Data in B and G were pooled from at least two independent experiments with n =  
1127 11-12 mice (B) and n = 60-279 tracks per condition (G), and D is from one of two representative  
1128 experiments with 21-24 cells per condition and n = 411-777 individual F-actin spots tracked per  
1129 condition (except T<sub>N</sub> + CK on ICAM-1: 144 F-actin spots). Statistical analysis was done by a  
1130 Kruskal-Wallis test against LN T<sub>N</sub> (B) or between all columns (D, G). \*\*, p < 0.01; \*\*\*, p < 0.001.

1131

1132 **Figure 2. SMG T<sub>RM</sub> display high constitutive actomyosin contractility and bleb formation**  
1133 **during spontaneous migration. A.** Flow cytometry analysis of MYH9-GFP-expressing T<sub>CM</sub>, T<sub>EM</sub>  
1134 and SMG T<sub>RM</sub> DsRed<sup>+</sup> OT-I T cells. **B.** MYH9-GFP dynamics in DsRed<sup>+</sup> OT-I T cells under agarose  
1135 migration. Empty arrowhead indicates leading edge protrusion. Time in min:s; Scale bar, 10  $\mu$ m. **C.**  
1136 Flow cytometry analysis of pMLC in endogenous T<sub>N</sub> and OT-I T<sub>CM</sub>, T<sub>EM</sub> and SMG T<sub>RM</sub>. **D.**  
1137 Immunofluorescent analysis of pMLC in spleen and SMG memory OT-I T cells. **E.** Scheme of Rho-  
1138 triggered pMLC generation and selected inhibitors. **F.** Wide-field fluorescence microscopy images  
1139 of SMG T<sub>RM</sub> under agarose migration in presence of inhibitors. Time in min:s; Scale bar, 10  $\mu$ m. **G.**  
1140 Dynamic and morphometric analysis of SMG T<sub>RM</sub> displacement. **H.** Scheme of F-actin-filled  
1141 protrusion versus bleb formation in migrating LifeAct-GFP x mT/mG SMG T<sub>RM</sub>. **I.** High temporal  
1142 resolution protrusion analysis of migrating LifeAct-GFP x mT/mG SMG T<sub>RM</sub> OT-I under 2D and 3D  
1143 confinement. Empty arrowheads indicate F-actin-filled protrusions, filled arrowheads indicate

blebs. Scale bar, 10  $\mu$ m. Bars in A and C represent median. Data in A (n = 6 mice), C (n = 9-11 mice), D (n = 63-65 cells), and G (n = 184-239 tracks) were pooled from at least two independent experiments and analyzed by ANOVA (A, C), Mann-Whitney test (D) or a Kruskal-Wallis test against control (G). \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001.

**Figure 3. Exocrine gland T<sub>RM</sub> react to mechanical load of their environment with motility. A.** Experimental layout. **B.** Wide-field fluorescence microscopy images of SMG T<sub>RM</sub> migrating without or with confinement. **C.** Exemplary tracks. **D.** Dynamic and morphometric analysis of T<sub>RM</sub> motility with or without confinement. Scale bar, 10  $\mu$ m. **E.** Exemplary tracks and wide-field fluorescence microscopy images of SMG T<sub>RM</sub> migrating under distinct mechanical load. Scale bar, 5  $\mu$ m. **F.** Dynamic and morphometric analysis of T<sub>RM</sub> motility under distinct mechanical load. **G, H.** Exemplary tracks (G) and dynamic and morphometric analysis of lacrimal gland (LG) and small intestine (SI) T<sub>RM</sub> motility (H) on HSA-coated plates under confinement. Data in D (n = 454-1000 tracks), F (n = 159-323 tracks) and H (n = 68-242 tracks) were pooled from at least two independent experiments and analyzed using a Student's t-test or Mann-Whitney test (D, H) or a Kruskal-Wallis test between all columns (F). \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001.

**Figure 4. Confinement-induced nuclear deformation correlates with Ca<sup>2+</sup> and AA-dependent autonomous SMG T<sub>RM</sub> motility. A.** Confocal image of nuclear deformation in under agarose confinement. Scale bar, 5  $\mu$ m. **B.** Projected maximum cross-section area and maximum nuclear height with and without confinement (n = 20-23 nuclei). **C.** Schematic layout, micrograph and exemplary tracks of SMG T<sub>RM</sub> in confinement chamber. Scale bar, 5  $\mu$ m. **D.** Dynamic and morphometric analysis of T<sub>RM</sub> motility in confinement chambers. **E.** Scheme of confinement-induced nuclear stretching and selected inhibitors of “evasive reflex” mediated by Ca<sup>2+</sup> flux from intracellular stores, induction of PLA2 activity and release of arachidonic acid (AA). 2APB, BAPTA-AM and the AA analogue AACOCF3 are inhibitors of intracellular Ca<sup>2+</sup> channels, intracellular Ca<sup>2+</sup> and PLA2 activity, respectively. **F.** Wide-field fluorescence microscopy images of SMG T<sub>RM</sub> under agarose migration in presence of AACOCF3 and AA. Time in min:s; Scale bar, 10  $\mu$ m. **G.** Dynamic and morphometric analysis of T<sub>RM</sub> motility in presence of AACOCF3 and AA. **H.** Wide-field

1173 fluorescence microscopy images of SMG T<sub>RM</sub> under agarose migration in presence of BAPTA-AM  
1174 and 2ABP. Time in min:s; Scale bar, 10  $\mu$ m. **I.** Dynamic and morphometric analysis of T<sub>RM</sub> motility  
1175 under agarose in presence of BAPTA-AM and 2ABP. Data in D (n = 35-43 tracks), G (n = 296-708  
1176 tracks) and I (n = 63-199 tracks) were pooled from at least two independent experiments and  
1177 analyzed using Student's t-test and Mann-Whitney test (D), or Kruskal-Wallis against control (G, I).  
1178 \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001.

1179

1180 **Figure 5. Blocking mechanosensing impairs T<sub>RM</sub> target cell identification.** **A.** Experimental  
1181 layout. **B.** Wide-field fluorescence microscopy images of confined SMG T<sub>RM</sub> tracking of dispersed  
1182 target cells with and without AACOCF3. Time in min:s; scale bar, 30  $\mu$ m. **C.** Quantification of T<sub>RM</sub> –  
1183 target B cell synapse formation with or without AACOCF3. Data in C (n = 139-341 synapses) were  
1184 pooled from two independent experiments and analyzed by Mann-Whitney test. \*, p < 0.05.

1185

1186 **Figure 6. Blocking mechanosensing disrupts *in vivo* SMG T<sub>RM</sub> migration.** **A.** Confocal image  
1187 of SMG T<sub>RM</sub> (arrowhead) *in situ*. Scale bar, 5  $\mu$ m. **B.** Scheme of BAPTA-AM superfusion. **C.** 2PM  
1188 images of SMG T<sub>RM</sub> migration before (baseline) and after 50  $\mu$ M BAPTA-AM superfusion. Scale  
1189 bar, 10  $\mu$ m. **D-G.** Speeds (D), meandering index (E), arrest coefficient (F) and sphericity (G) of T<sub>RM</sub>  
1190 before and 1-4 h after superfusion with BAPTA-AM. **H.** Experimental layout of MCMV-3D- $\Delta$ vRAP  
1191 rechallenge. **I.** Confocal sections of MCMV-challenged SMG in control (DMSO)-and AACOCF3-  
1192 treated recipients. Dotted line marks outline of SMG section, square depicts insert. Scale bar, 500  
1193 and 50 (insert)  $\mu$ m. **J.** Number of T<sub>RM</sub> per area in control- and AACOCF3-treated SMG. **K.** Percent  
1194 of clustered T<sub>RM</sub> in control-and AACOCF3-treated recipients in 10-14 sections from 3 independent  
1195 experiments (n = 24 control- and AACOCF3-treated mice in total). **L.** Graphical summary. Data in  
1196 D-G (n = 207-323 tracks), J and K are pooled from at least two experiments and analyzed using  
1197 Kruskal-Wallis (D-G), Student's t-test (J) or Mann-Whitney test (K). \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p <  
1198 0.001.

1199




Figure 1




Figure 2




Figure 3






Figure 4




Figure 5

1208

1209




Figure 6

1212 **Supplemental Material and Methods**

1213 *CRISPR/Cas9-mediated MYH9 deletion in T cells*

1214 Myh9 crisprRNAs (crRNA) were designed using DESKGEN online tool ([www.deskgen.com](http://www.deskgen.com)). Alt-R®  
1215 CRISPR-Cas9 crRNA (custom design), trans-activator RNA (tracrRNA) (1072534) and Alt-R®  
1216 CRISPR-Cas9 negative crRNA (226567203) were purchased from Integrated DNA Technologies  
1217 (Coralville, IA, USA) and reconstituted at 100 µM with nuclease free duplex buffer (Integrated DNA  
1218 Technologies). Nucleofection was performed as the following: One µL each of crRNA and  
1219 tracrRNA were annealed to form gRNA at 95°C for 5 min using a thermal cycler and cooled to  
1220 room temperature. Annealed gRNA was mixed with TrueCut Cas9 v2 (A36499, Thermo Fisher  
1221 Scientific, Basel, Switzerland) at a ratio of gRNA : Cas9 = 1.8 µL : 1.2 µL (equivalent to 90 pmol :  
1222 36 pmol) and left at room temperature for > 10 min to generate RNP complex. Isolated naïve  
1223 DsRed<sup>+</sup> MYH9-GFP<sup>+</sup> OT-I CD8<sup>+</sup> T cells were resuspended in Primary Cell 4D-Nucleofector™ X Kit  
1224 S (Lonza, Basel, Switzerland) buffer solution at a cell concentration of 5 x 10<sup>6</sup> cells in 20 µL. The  
1225 entire cell suspension was mixed with 3 µL per complex RNP solution and added to  
1226 Nucleocuvette™ strip well. Cells were then nucleofected using a 4D-Nucleofector™ with X-Unit  
1227 (V4XP-4032 and V4XP-9096, Lonza). Three RNP complexes in 9 µL were used per reaction. After  
1228 nucleofection, 100 µL of pre-warmed complete medium containing 20 ng/mL recombinant mouse  
1229 IL-7 was added to each Nucleocuvette™. Cells were gently mixed by pipetting and aliquoted into a  
1230 flat-bottom 96-well plate. Cells were cultured in a total volume of 200 µL complete medium  
1231 containing rmlIL-7 at 2 x 10<sup>6</sup> CD8<sup>+</sup> T cells for 8-14 days at 37°C in a humidified 5% CO<sub>2</sub>  
1232 atmosphere. The 3 crRNA sequences used in this study are listed below:

GCTGGTACTCACGAATCGAG
CATCTCGGCCAAGTATGCAG
CAAATACAAGGCCTCCATCG

1233

1234 *NanoString analysis*

1235 Endogenous PI<sup>-</sup> CD44<sup>low</sup> CD62L<sup>+</sup> CD8<sup>+</sup> T<sub>N</sub> and PI<sup>-</sup> GFP<sup>+</sup> CD8<sup>+</sup> CD44<sup>high</sup> CD62L<sup>+</sup> (= spleen OT-I  
1236 T<sub>CM</sub>), PI<sup>-</sup> GFP<sup>+</sup> CD8<sup>+</sup> CD44<sup>high</sup> CD62L<sup>-</sup> (= spleen OT-I T<sub>EM</sub>) and PI<sup>-</sup> GFP<sup>+</sup> CD8<sup>+</sup> CD103<sup>+</sup> (= SMG  
1237 T<sub>RM</sub>) were sorted in triplicates and 4.5 x 10<sup>4</sup> cells of each lysed according to the manufacturer's

1238 instructions (NanoString, UK). Lysates of were hybridized to a set of customized probes covering  
1239 putative factors involved in migration and mechanosensing. The counts for each sample were  
1240 normalized based on housekeeping gene expression.

1241

1242 **Supplemental Figure legend**

1243 **Figure S1. Flow cytometry of memory T cells.** **A.** Gating strategy of spleen (pregated on  
1244 lymphocyte FSC/SSC, singlets, CD45<sup>+</sup>/CD8<sup>+</sup>) and SMG (pregated on lymphocyte FSC/SSC,  
1245 singlets, CD45<sup>+</sup>) single cell suspensions of LCMV-OVA infected mice in memory phase. End.,  
1246 endogenous T cells. **B, C.** Flow cytometry analysis of T<sub>N</sub>, T<sub>CM</sub>, T<sub>EM</sub> and SMG T<sub>RM</sub> cell size (mean  
1247 FSC, B) and normalized pCofilin levels (C). **D.** Flow cytometry analysis of DOCK2-GFP-  
1248 expressing polyclonal CD8<sup>+</sup> T<sub>CM</sub>, T<sub>EM</sub> and SMG T<sub>RM</sub> of LCMV-OVA infected mice in memory phase  
1249 **E, F.** Flow cytometry analysis of T<sub>N</sub>, T<sub>CM</sub>, T<sub>EM</sub> and SMG T<sub>RM</sub> ERM (E) and pERM (F) levels. Data  
1250 were pooled from at least two experiments (n = 9-12 mice) and analyzed by a Kruskal-Wallis test  
1251 against LN T<sub>N</sub> (B, C, E, F) or between all columns (D). \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001.

1253 **Figure S2. Outline of morphometric analysis.** After determining the cell contour (1), cell  
1254 trajectories are defined for motility parameters (2) together with local curvatures (3) to identify  
1255 protrusions (4). The uropod is defined as the protrusion in the most opposite direction than the  
1256 positive displacement of the cell (following its trajectory), and is excluded from the protrusion  
1257 analysis. For more details, refer to the Material and Method section.

1259 **Figure S3. Autonomous SMG T<sub>RM</sub> motility requires constitutive DOCK2-Rac-Arp2/3**  
1260 **signaling.** **A.** Scheme of Arp2/3-mediated leading edge F-actin generation and selected inhibitors.  
1261 **B.** DOCK2-GFP distribution in polarized T<sub>RM</sub>. Quantification pooled from 7 cells, mean ± SEM.  
1262 Scale bar, 10 μm. **C.** Wide-field fluorescence microscopy images of SMG T<sub>RM</sub> under agarose  
1263 migration in presence of CPYPP, CK666 and ML141. Time in min:s; Scale bar, 10 μm. **D.** Dynamic  
1264 and morphometric analysis of SMG T<sub>RM</sub> displacement. **E.** Wide-field fluorescence microscopy  
1265 images of SMG T<sub>RM</sub> under agarose migration in presence of W56 or control F56 peptide. Time in  
1266 min:s; Scale bar, 10 μm. **F.** Dynamic and morphometric analysis of SMG T<sub>RM</sub> displacement. **G.**  
1267 Intravital image sequence of WT (white line) and DOCK2<sup>-/-</sup> SMG T<sub>RM</sub> tracks (white dashed line).  
1268 Time in min:s; Scale bar, 10 μm. **H, I.** Speeds and meandering index of WT and DOCK2<sup>-/-</sup> SMG (H)  
1269 T<sub>RM</sub> and DOCK2<sup>-/-</sup> SMG T<sub>RM</sub> (I) assessed by 2PM. Data in D (n = 38-239 tracks), F (n = 155-363  
1270 tracks), H (n = 97-439 tracks) and I (n = 69-439 tracks) were pooled from at least two independent

1271 experiments (except F: ML141, one exp. with n = 129 tracks) and analyzed by a Kruskal-Wallis test  
1272 against control (D) or Mann-Whitney test (F, H, I). \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001.

1273

1274 **Figure S4. Genetic depletion of MYH9 impairs T cell development and *in vivo* expansion. A.**

1275 Flow cytometry analysis of MYH9 levels in control (wild type, WT) and CD4-cre x MYH9<sup>fl/fl</sup> OT-I T  
1276 cells. Recovered peripheral T cells contained comparable MYH9 levels as non-deleted control cells  
1277 using this early cre inducer model, suggesting thymic block of T cell development in absence of  
1278 MYH9. **B.** Experimental layout of CRISPR/Cas9-mediated deletion of MYH9 in MYH-GFP reporter  
1279 OT-I T cells and representative flow cytometry plot of control and MYH9-depleted OT-I T cells prior  
1280 to adoptive transfer (n = 13 mice). Myosin IIA depletion is indicated by loss of GFP signal in MYH9-  
1281 GFP OT-I T cells. RNP, Cas9 ribonuclein protein complex. **C.** Flow cytometry plots showing loss of  
1282 MYH9-depleted OT-I T cells on day 6 p.i. with LCMV-OVA.

1283

1284 **Figure S5. SMG T<sub>RM</sub> motility requires Rho signaling. A-D.** Under agarose SMG T<sub>RM</sub> motility

1285 after inhibition of Rho (A, B) and Formins (F, G), and under agarose SMG T<sub>RM</sub> motility with  
1286 polystyrene beads + pluronic after inhibition of ROCK (C, D). Time in min:s; scale bar, 10  $\mu$ m. **E.**  
1287 Speeds and meandering index of control (baseline) and Y-27632-treated SMG containing WT T<sub>RM</sub>  
1288 determined by 2PM. **F, G.** Under agarose SMG T<sub>RM</sub> motility after inhibition of Formins. Data in D (n  
1289 = 37-92 tracks) and E (n = 102-133 tracks) were pooled from two experiments (except B: one exp.  
1290 with n = 52-98 tracks) and analyzed by a Mann-Whitney test. \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p <  
1291 0.001.

1292

1293 **Figure S6. T cell motility under confinement. A.** Speeds and cell area of T<sub>RM</sub> and T<sub>N</sub> in 4 and 2-

1294  $\mu$ m high chambers. **B.** Example of T<sub>RM</sub> membrane rupture (arrowhead) in a 2  $\mu$ m-high confinement  
1295 chamber. Time in min:s; scale bar, 10  $\mu$ m. **C.** Speeds and meandering index of T<sub>N</sub> under agarose  
1296 on ICAM-1 in presence or absence of AA, CCL21 and AACOCF3. **D.** Speeds and meandering  
1297 index of T<sub>RM</sub> under agarose on ICAM-1 and CXCL10  $\pm$  AACOCF3. Data in A (n = 25-89 tracks) and  
1298 C (n = 142-609 tracks) are pooled from 2 independent experiments and analyzed using ANOVA  
1299 with Sidak's multiple comparison test (speeds) or Kruskal-Wallis (meandering index). Data in D is

1300 from one experiment (n = 18-40 tracks) and analyzed by unpaired t-test (speeds) and Mann-  
1301 Whitney (meandering index). \*, p < 0.05; \*\*\*, p < 0.001.

1302

1303 **Figure S7. Gene expression analysis. A, B.** Expression of *Pla2g4a* in T cell subsets in Immgen  
1304 database (A; shown as robust multichip normalization, RMA) and qPCR (B). DN, double negative  
1305 thymocytes. **C.** Nanostring analysis of subset-specific marker expression in sorted OT-I T<sub>N</sub>, T<sub>CM</sub>,  
1306 T<sub>EM</sub> and T<sub>RM</sub>. **D-G.** Nanostring expression analysis of *Pla2g* isoforms (D), InsP3R-encoding genes  
1307 (E), nuclear cytoskeleton components (F) and nuclear-cytoplasmic anchoring components (G) in  
1308 T<sub>N</sub>, T<sub>CM</sub>, T<sub>EM</sub> and T<sub>RM</sub>.

1309

1310 **Figure S8. Characterization of SMG viral rechallenge experiment and inhibitors. A, B.**  
1311 Speeds (A) and meandering index (B) of T<sub>RM</sub> before (n = 386 tracks) and 1-4 h after administration  
1312 of AACOCF3 (n = 924 tracks) determined by 2PM. **C.** Exemplary flow cytometry plot of CD69 and  
1313 CD103 staining on SMG T<sub>RM</sub>. **D.** Quantification of SMG T<sub>RM</sub> numbers at 3 d of DMSO or AACOCF3  
1314 treatment in presence or absence of anti- $\alpha$ 4 and anti-LFA-1 ( $\alpha_L$ ) mAb block (n = 3-5 mice from 2  
1315 independent experiments). Bars depict mean  $\pm$  SD. **E.** Experimental layout of Wharton's duct  
1316 infection for MCMV-3D- $\Delta$ vRAP rechallenge into one SMG lobe and example image of TRITC-  
1317 dextran injection. Line marks outline of SMG lobes. **F.** T<sub>RM</sub> numbers in uninfected (blue) and  
1318 contralaterally infected (dark red) SMG lobes from one of two independent experiments (n = 3 mice  
1319 per condition). **G.** Percentage of blood CD3<sup>+</sup> following FTY720 treatment (n = 8 mice from 2  
1320 independent experiments). Bars depict mean  $\pm$  SD. **H.** Confocal SMG section depicting a rare  
1321 mCherry<sup>+</sup> MCMV-infected cell (arrowhead) in SMG at 68 h p.i. Scale bar, 50  $\mu$ m. Right plot depicts  
1322 number of mCherry<sup>+</sup> viral foci per area (n = 4 sections from one experiment). Data in A, G and H  
1323 were analyzed with an unpaired t-test and data in B with a Mann-Whitney test. Data in D were  
1324 analyzed using ANOVA. \*\*, p < 0.01; \*\*\*, p < 0.001.

1325



1326 **Supplementary movie legend**

1327 **Movie 1. Intravital imaging of OT-I T<sub>RM</sub> migration in SMG during the memory phase following**

1328 **LCMV-OVA infection.** SHG, second harmonic generation. Time in min:s. Image sequence

1329 recorded using the LaVision Biotec TrimScope system.

1330 **Movie 2. TIRF time-lapse video of F-actin dynamics in LifeAct-GFP<sup>+</sup> OT-I T<sub>N</sub> in under**

1331 **agarose assay.** Time in min:s. Image sequence recorded using the DeltaVision system.

1332 **Movie 3. TIRF time-lapse video of F-actin dynamics in LifeAct-GFP<sup>+</sup> SMG OT-I T<sub>RM</sub> in under**

1333 **agarose assay.** Time in min:s. Image sequence recorded using the DeltaVision system.

1334 **Movie 4. Widefield fluorescent microscopy time-lapse video of OT-I T<sub>N</sub> in under agarose**

1335 **assay on HSA or CCL19 and ICAM-1.** Time in min:s. Image sequence recorded using the

1336 DeltaVision system.

1337 **Movie 5. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under**

1338 **agarose assay on HSA or CXCL10, CXCL10 and ICAM-1.** Time in min:s. Image sequence

1339 recorded using the DeltaVision system.

1340 **Movie 6. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under**

1341 **agarose assay on HSA and CPYPP or CK666.** Time in min:s. Image sequence recorded using

1342 the DeltaVision system.

1343 **Movie 7. Intravital imaging of DOCK2<sup>-/-</sup> and WT OT-I T<sub>RM</sub> in SMG during the memory phase**

1344 **following LCMV-OVA infection.** SHG, second harmonic generation. Time in min:s. Image

1345 sequence recorded using the LaVision Biotec TrimScope system.

1346 **Movie 8. Widefield fluorescent microscopy time-lapse video of DsRed<sup>+</sup> MYH-GFP<sup>+</sup> SMG OT-I**

1347 **T<sub>RM</sub> in under agarose assay on HSA.** Time in min:s. Image sequence recorded using the

1348 DeltaVision system.

1349 **Movie 9. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under**

1350 **agarose assay on HSA and MLCK or Y-27632.** Time in min:s. Image sequence recorded using

1351 the DeltaVision system.

1352 **Movie 10. Widefield fluorescent microscopy time-lapse video of mT/mG<sup>+</sup> LifeAct-GFP<sup>+</sup> or**

1353 **DOCK2-GFP<sup>+</sup> SMG OT-I T<sub>RM</sub> in under agarose assay, followed by confocal microscopy time-**

1354 **lapse image sequence of mT/mG<sup>+</sup> LifeAct-GFP<sup>+</sup> SMG OT-I T<sub>RM</sub> in 3D collagen matrix.** Time in  
1355 min:s. Image sequence recorded using the DeltaVision or Leica confocal imaging system.

1356 **Movie 11. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in**  
1357 **confinement chamber with micropillars of 7 μm or 4 μm height.** Time in min:s. Image  
1358 sequence recorded using the DeltaVision system.

1359 **Movie 12. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under**  
1360 **agarose assay on HSA with EtOH, AACOCF<sub>3</sub> and AACOCF<sub>3</sub> + AA.** Time in min:s. Image  
1361 sequence recorded using the DeltaVision system.

1362 **Movie 13. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under**  
1363 **agarose assay on HSA with DMSO, BAPTA-AM and 2APB.** Time in min:s. Image sequence  
1364 recorded using the DeltaVision system.

1365 **Movie 14. Widefield fluorescent microscopy time-lapse video of SMG OT-I T<sub>RM</sub> in under**  
1366 **agarose assay on HSA with OVA<sub>257-264</sub>-pulsed and unpulsed B cells with or without**  
1367 **AACOCF<sub>3</sub>.** Scale bar, 10 μm; time in min:s. Image sequence recorded using the DeltaVision  
1368 system.

1369 **Movie 15. Intravital imaging of SMG T<sub>RM</sub> before and after BAPTA-AM (50 μM) superfusion.**  
1370 Scale bar, 20 μm. Time in min:s. Image sequence recorded using the LaVision Biotec TrimScope  
1371 system.

1372






Figure S1



# 1. Determining cell contour





## 2. Forming cell trajectories to determine displacement direction



## 3. Calculating local curvatures




## 4. Defining the protrusions



u = uropod  
p = protrusion

Figure S2



1375 Figure S3




Figure S4




Figure S5

1377  
1378




Figure S6

1379  
1380






Figure S7




Figure S8